ClinicalTrials.gg
CompletedNCT04816643Updated May 28, 2026Results posted

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

A Phase 3 interventional study of Biological/Vaccine: BNT162b2 10mcg and BNT162b2 20mcg in SARS-CoV-2 Infection, COVID-19, sponsored by BioNTech SE. Completed at 128 sites in 6 countries. Open to participants aged 6 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11,837
Allocation
Non-randomized
Ages
6 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
3rd of 54
11,837 · median 575
Started
2021
with 29 others
Phase 3
18 of 54
1 open now
Registered
12th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 3rd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 6 Months to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a Phase 1/2/3 study in healthy children.

Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age may subsequently be evaluated.

Read the detailed description

Phase 1 Dose-Finding

Is the open-label dose-finding portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to \<12 years, ≥2 to \<5 years, and ≥6 months to \<2 years of age).

Dose finding is being initiated in this study in participants ≥5 to \<12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.

Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the third dose of BNT162b2 will be based on age at the time of vaccination: participants \<5 years of age at the time of the third dose will receive the 3-µg dose level, participants ≥5 to \<12 years of age at the time of the third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the third dose will receive the 30-µg dose level.

Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the selected BNT162b2 dose level for Phase 2/3. Participants will also have blood drawn prior to Dose 3 and 1, 6, and 12 months after Dose 3.

Phase 2/3 Selected-Dose

Is the portion of the study that will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from the Phase 1 dose-finding portion of the study. Efficacy will be evaluated within or across age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases in those age groups.

Participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at (1) baseline and 1 month after Dose 2 and (2) baseline and 1 month after Dose 3. The persistence of the immune response will be based on immunogenicity data collected in participants at (1) baseline and 1 and 6 months after Dose 2 and (2) baseline and 1, 6, 12, and 18 months after Dose 3. In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed in participants ≥5 to \<12 years of age.

At designated US sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. Additional samples will be obtained prior to Dose 3 and 1 month after Dose 3 (original BNT162b2 group only). These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.

At the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study. Participants who originally received placebo and become eligible for receipt of BNT162b2 or another COVID-19 vaccine according to local or national recommendations prior to the 6 month follow-up visit (Visit 5 or 405) (detailed separately and available in the electronic study reference portal) will have the opportunity to receive BNT162b2 (10 µg or 3 µg) based on age at the time of vaccination.

Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants \<5 years of age at the time of the second/third dose will receive the 3-µg dose level, participants ≥5 to \<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.

Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing

If testing of troponin I levels in individuals who did not receive BNT162b2 indicates that troponin I level could be a reliable indicator of potential subclinical myocarditis, obtaining serum samples for potential troponin I testing during the period of increased risk of clinical myocarditis may help characterize the absence/presence and frequency of subclinical myocarditis. To assess, an additional group of participants will be included: ≥5 to \<12 years: randomized 2:1 to receive BNT162b2 10 µg or placebo, and ≥12 to \<16 years of age: open-label receipt of BNT162b2 30 µg.

Update as part of protocol amendment 7: All participants will receive a third dose of BNT162b2. For all participants (≥5 to \<12 and ≥12 to \<16 years of age), the third dose will occur at least 5 months after Dose 2.

The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants ≥5 to \<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.

Update as part of protocol amendment 8: The Lower-Dose Evaluation portion of the protocol has been removed.

Participation in the study will cease 6 months after the third dose of BNT162b2.

03

Conditions studied

  • SARS-CoV-2 Infection, COVID-19

Browse trials for

Keywords

  • COVID-19
  • Coronavirus Vaccine
  • SARS-CoV-2
  • RNA Vaccine
  • mRNA Vaccine
04

Who can participate

Ages eligible
6 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants ≥6 months to \<12 years of age, at the time of randomization, at Visit 1 for the dose-finding/selected-dose evaluation. For the obtaining-serum-samples-for-potential-troponin I-testing portion of the study: Male or female participants between ≥5 and \<16 years of age.
  2. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  3. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

    Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.

  4. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.
  5. Negative urine pregnancy test for female participants who are biologically capable of having children.
  6. Female participant of or male participant able to father children who is willing to use a highly effective method of as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.
  7. The participant or participant's parent(s)/legal guardian is capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).

Exclusion criteria

Exclusion Criteria

  1. Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
  2. Phase 1 only: Known infection with , , or .
  3. Receipt of medications intended to prevent COVID-19.
  4. Previous or current diagnosis of MIS-C.
  5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results
  6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  7. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  8. Individuals with a history of disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
  9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  10. Female who is pregnant or breastfeeding.
  11. Previous vaccination with any coronavirus vaccine.
  12. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic , eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  13. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.
  14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  15. Previous participation in other studies involving study intervention containing LNPs.
  16. Participants who are direct descendants (child or grandchild) of site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11,837 participants (actual)

Study arms

  • Experimental
    Low/Mid-Dose, ≥5 to <12 Years

    Low/Mid-Dose (10mcg), 2 doses 21 days apart

    Biological: Biological/Vaccine: BNT162b2 10mcg

  • Experimental
    Mid-Dose, ≥5 to <12 Years

    Mid-Dose, (20mcg), 2 doses 21 days apart

    Biological: BNT162b2 20mcg

  • Experimental
    High-Dose, ≥5 to <12 Years

    High-Dose (30mcg), 2 doses 21 days apart

    Biological: BNT162b2 30mcg

  • Experimental
    Low/Mid-Dose, ≥2 to < 5 Years

    Low/Mid-Dose (10mcg), 2 doses 21 days apart

    Biological: Biological/Vaccine: BNT162b2 10mcg

  • Experimental
    Mid-Dose, ≥2 to <5 Years

    Mid-Dose, (20mcg), 2 doses 21 days apart

    Biological: BNT162b2 20mcg

  • Experimental
    High-Dose, ≥2 to <5 Years

    High-Dose, (30mcg), 2 doses 21 days apart

    Biological: BNT162b2 30mcg

  • Experimental
    Low/Mid-Dose, ≥6 Months to <2 Years

    Low/Mid-Dose, (10mcg), 2 doses 21 days apart

    Biological: Biological/Vaccine: BNT162b2 10mcg

  • Experimental
    Mid-Dose, ≥6 Months to <2 Years

    Mid-Dose, (20mcg), 2 doses 21 days apart

    Biological: BNT162b2 20mcg

  • Experimental
    High-Dose, ≥6 Months to <2 Years

    High-Dose, (30mcg), 2 doses 21 days apart

    Biological: BNT162b2 30mcg

  • Placebo comparator
    Placebo, ≥6 Months to <2 Years

    Other: Placebo

  • Placebo comparator
    Placebo, ≥2 to <5 Years

    Other: Placebo

  • Placebo comparator
    Placebo, ≥5 to <12 Years

    Other: Placebo

  • Experimental
    Low-Dose, ≥6 Months to <2 Years

    Low-Dose (3mcg), 2 doses 21 doses apart

    Biological: Biological/Vaccine: BNT162b2 3mcg

  • Experimental
    Low-Dose, ≥2 to <5 Years

    Low-Dose (3mcg), 2 doses 21 days apart

    Biological: Biological/Vaccine: BNT162b2 3mcg

  • Experimental
    High-Dose, 12 to <16 Years (Troponin I Testing)

    High-Dose (30mcg), 3 doses

    Biological: BNT162b2 30mcg

  • Experimental
    Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)

    Low/Mid-Dose (10mcg), 3 doses

    Biological: Biological/Vaccine: BNT162b2 10mcg

  • Experimental
    Placebo, ≥5 to <12 Years (Troponin I Testing)

    Other: Placebo

  • Experimental
    Low-Dose, ≥6 Months to <2 Years (3-dose regimen)

    Low-Dose (3mcg), 3 doses

    Biological: Biological/Vaccine: BNT162b2 3mcg

  • Experimental
    Low-Dose, ≥2 to <5 Years (3-dose regimen)

    Low-Dose (3mcg), 3 doses

    Biological: Biological/Vaccine: BNT162b2 3mcg

  • Placebo comparator
    Placebo, ≥6 Months to <2 Years (3-dose regimen)

    Other: Placebo

  • Placebo comparator
    Placebo, ≥2 to <5 Years (3-dose regimen)

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age

    Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.

    Time frame: Phase 1: From Day 1 to Day 7 after Dose 1

  2. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  3. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  4. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 degree Celsius (deg C); categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 1

  5. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  6. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  7. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 1

  8. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  9. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  10. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 1

  11. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  12. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  13. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 1

  14. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  15. Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  16. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 1

  17. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 2

  18. Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 1: Day 1 to Day 7 after Dose 3

  19. Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2

  20. Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3

  21. Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age

    A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2

  22. Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3

  23. Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2

  24. Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3

  25. Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2

  26. Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3

  27. Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2

  28. Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3

  29. Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2

  30. Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

    Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3

  31. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  32. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  33. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  34. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm),moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  35. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  36. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  37. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  38. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  39. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  40. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  41. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  42. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  43. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  44. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  45. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  46. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  47. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2

  48. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2

  49. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3

  50. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3

  51. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  52. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  53. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\>=0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm),severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  54. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  55. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  56. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  57. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis\[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  58. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  59. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  60. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  61. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  62. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  63. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  64. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  65. Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  66. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1

  67. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2

  68. Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

    Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3

  69. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  70. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  71. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2

  72. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3

  73. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  74. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  75. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2

  76. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3

  77. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  78. Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  79. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2

  80. Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3

  81. Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection

    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.

    Time frame: C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  82. Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

    Seroresponse is defined as achieving a \>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  83. Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

    GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.

    Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  84. Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

    Seroresponse is defined as achieving a \>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  85. Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

    GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.

    Time frame: C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  86. Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection

    Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  87. Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection

    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.

    Time frame: C4591007 (>=2 to <5 years):1 Month after Dose 2 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2

  88. Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection

    Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 3 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2

  89. Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection

    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.

    Time frame: C4591007 (>=6 months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2

  90. Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection

    Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: C4591007 (>=6 Months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 month after Dose 2

Secondary outcomes

  1. Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection

    GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

    Time frame: Phase 1: 7 days post Dose 2

  2. Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection

    GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

    Time frame: Phase 1: 7 days post Dose 2

  3. Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection

    GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

    Time frame: Phase 1: 7 days post Dose 2

  4. Phase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: Phase 2/3: Before Dose 1 and 1 Month after Dose 2

  5. Phase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

    Time frame: Phase 2/3: From Dose 3 set: Pre-Dose 3 and 1 Month after Dose 3

  6. Phase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.

    Time frame: Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3

  7. Phase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.

    Time frame: Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3

  8. Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection

    GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\* LLOQ in the analysis.

    Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2

  9. Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection

    GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.

    Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3

  10. Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

    Time frame: Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3

  11. Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.

    Time frame: Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3

  12. Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age

    COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.

    Time frame: Phase 2/3: From 7 days after Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)

  13. Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age

    COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.

    Time frame: Phase 2/3: From 7 Days After Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)

  14. Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age

    COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.

    Time frame: Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)

  15. Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age

    COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.

    Time frame: Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)

07

Results

Posted May 28, 2026

Participant flow

The study consisted of 2 parts, Phase 1 and Phase 2/3.

Phase 1
Participant flow — Phase 1
MilestonePhase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of AgePhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3:Troponin Group:Placebo:5 to <12 Years of AgePhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Started1616321616412000000000
Vaccination 11616321616412000000000
Vaccination 21616321616412000000000
Vaccination 3151327168412000000000
Safety population1616321616412000000000
Completed87142321000000000
Not completed89181413211000000000
Withdrew: Protocol violation1285916000000000
Withdrew: Other6348214000000000
Withdrew: Withdrawal by parent/guardian/participants1341201000000000
Withdrew: Lost to follow-up0120000000000000
Phase 2/3
Participant flow — Phase 2/3
MilestonePhase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of AgePhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3:Troponin Group:Placebo:5 to <12 Years of AgePhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Started000000014587182368117331091538518260506
Vaccination 1000000014587182368117331091538518260506
Vaccination 2000000014456722343107331011532514110496
Vaccination 3000000013242372093405255504290452
Safety population000000014587182368117331091538518260487
First dose of bnt162b2 in open label period after unblinding0000000058107870126202430
Second dose of bnt162b2 in open label period after unblinding0000000056907720125402390
Third dose of bnt162b2 in open label period after unblinding0000000053406940104802110
Completed000000071226112144061605635395188443
Not completed0000000746457115476715049031237263
Withdrew: Protocol violation000000025161488247427231206
Withdrew: Other000000046522146417186471140
Withdrew: Withdrawal by parent/guardian/participants0000000199196428458816543663740
Withdrew: Lost to follow-up000000053231095512641141015
Withdrew: Physician decision0000000312100110
Withdrew: Adverse event0000000103000000
Withdrew: Refused further study procedures0000000000020000
Withdrew: Pregnancy0000000000000002

Outcome measures

PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age

Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.

Time frame:
Phase 1: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Redness: Any12.5 (1.6 to 38.3)0 (0.0 to 20.6)100.0 (39.8 to 100.0)16.7 (2.1 to 48.4)
Redness: Mild6.3 (0.2 to 30.2)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
Redness: Moderate6.3 (0.2 to 30.2)0 (0.0 to 20.6)75.0 (19.4 to 99.4)16.7 (2.1 to 48.4)
Redness: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Redness: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Swelling: Any18.8 (4.0 to 45.6)6.3 (0.2 to 30.2)50.0 (6.8 to 93.2)8.3 (0.2 to 38.5)
Swelling: Mild6.3 (0.2 to 30.2)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
Swelling: Moderate12.5 (1.6 to 38.3)6.3 (0.2 to 30.2)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Swelling: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Swelling: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Pain at the injection site: Any87.5 (61.7 to 98.4)93.8 (69.8 to 99.8)100.0 (39.8 to 100.0)83.3 (51.6 to 97.9)
Pain at the injection site: Mild68.8 (41.3 to 89.0)56.3 (29.9 to 80.2)50.0 (6.8 to 93.2)50.0 (21.1 to 78.9)
Pain at the injection site: Moderate18.8 (4.0 to 45.6)37.5 (15.2 to 64.6)50.0 (6.8 to 93.2)33.3 (9.9 to 65.1)
Pain at the injection site: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Pain at the injection site: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Redness: Any37.5 (15.2 to 64.6)18.8 (4.0 to 45.6)75.0 (19.4 to 99.4)16.7 (2.1 to 48.4)
Redness: Mild25.0 (7.3 to 52.4)6.3 (0.2 to 30.2)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Redness: Moderate12.5 (1.6 to 38.3)12.5 (1.6 to 38.3)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Redness: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
Redness: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Swelling: Any31.3 (11.0 to 58.7)18.8 (4.0 to 45.6)50.0 (6.8 to 93.2)0 (0.0 to 26.5)
Swelling: Mild12.5 (1.6 to 38.3)0 (0.0 to 20.6)50.0 (6.8 to 93.2)0 (0.0 to 26.5)
Swelling: Moderate18.8 (4.0 to 45.6)18.8 (4.0 to 45.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Swelling: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Swelling: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Pain at the injection site: Any87.5 (61.7 to 98.4)75.0 (47.6 to 92.7)100.0 (39.8 to 100.0)91.7 (61.5 to 99.8)
Pain at the injection site: Mild75.0 (47.6 to 92.7)50.0 (24.7 to 75.3)50.0 (6.8 to 93.2)83.3 (51.6 to 97.9)
Pain at the injection site: Moderate12.5 (1.6 to 38.3)25.0 (7.3 to 52.4)50.0 (6.8 to 93.2)8.3 (0.2 to 38.5)
Pain at the injection site: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Pain at the injection site: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 1: 5 to <12 Years BNT162b2 10 mcg
Redness: Any28.9 (15.4 to 45.9)
Redness: Mild21.1 (9.6 to 37.3)
Redness: Moderate7.9 (1.7 to 21.4)
Redness: Severe0 (0.0 to 9.3)
Redness: Grade 40 (0.0 to 9.3)
Swelling: Any13.2 (4.4 to 28.1)
Swelling: Mild10.5 (2.9 to 24.8)
Swelling: Moderate2.6 (0.1 to 13.8)
Swelling: Severe0 (0.0 to 9.3)
Swelling: Grade 40 (0.0 to 9.3)
Pain at the injection site: Any86.8 (71.9 to 95.6)
Pain at the injection site: Mild68.4 (51.3 to 82.5)
Pain at the injection site: Moderate18.4 (7.7 to 34.3)
Pain at the injection site: Severe0 (0.0 to 9.3)
Pain at the injection site: Grade 40 (0.0 to 9.3)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 degree Celsius (deg C); categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Fever: >=38.0 deg C6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)33.3 (9.9 to 65.1)
Fever:38.0 to 38.4 deg C6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)16.7 (2.1 to 48.4)
Fever: >38.4 to 38.9 deg C0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)16.7 (2.1 to 48.4)
Fever: >38.9 to 40.0 deg C0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fever: >40.0 deg C0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fatigue: Any50.0 (24.7 to 75.3)68.8 (41.3 to 89.0)100.0 (39.8 to 100.0)50.0 (21.1 to 78.9)
Fatigue: Mild37.5 (15.2 to 64.6)31.3 (11.0 to 58.7)25.0 (0.6 to 80.6)16.7 (2.1 to 48.4)
Fatigue: Moderate12.5 (1.6 to 38.3)37.5 (15.2 to 64.6)75.0 (19.4 to 99.4)33.3 (9.9 to 65.1)
Fatigue: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fatigue: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Headache: Any25.0 (7.3 to 52.4)31.3 (11.0 to 58.7)75.0 (19.4 to 99.4)33.3 (9.9 to 65.1)
Headache: Mild18.8 (4.0 to 45.6)31.3 (11.0 to 58.7)50.0 (6.8 to 93.2)25.0 (5.5 to 57.2)
Headache: Moderate6.3 (0.2 to 30.2)0 (0.0 to 20.6)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Headache: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Headache: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Chills: Any0 (0.0 to 20.6)25.0 (7.3 to 52.4)50.0 (6.8 to 93.2)16.7 (2.1 to 48.4)
Chills: Mild0 (0.0 to 20.6)18.8 (4.0 to 45.6)0 (0.0 to 60.2)8.3 (0.2 to 38.5)
Chills: Moderate0 (0.0 to 20.6)6.3 (0.2 to 30.2)50.0 (6.8 to 93.2)8.3 (0.2 to 38.5)
Chills: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Chills: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Any0 (0.0 to 20.6)6.3 (0.2 to 30.2)0 (0.0 to 60.2)8.3 (0.2 to 38.5)
Vomiting: Mild0 (0.0 to 20.6)6.3 (0.2 to 30.2)0 (0.0 to 60.2)8.3 (0.2 to 38.5)
Vomiting: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Any6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Mild6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened muscle pain: Any12.5 (1.6 to 38.3)25.0 (7.3 to 52.4)100.0 (39.8 to 100.0)0 (0.0 to 26.5)
New or worsened muscle pain: Mild6.3 (0.2 to 30.2)25.0 (7.3 to 52.4)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
New or worsened muscle pain: Moderate6.3 (0.2 to 30.2)0 (0.0 to 20.6)75.0 (19.4 to 99.4)0 (0.0 to 26.5)
New or worsened muscle pain: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened muscle pain: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened joint pain: Any6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
New or worsened joint pain: Mild6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)8.3 (0.2 to 38.5)
New or worsened joint pain: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
New or worsened joint pain: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened joint pain: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Fever: >=38.0 deg C12.5 (1.6 to 38.3)18.8 (4.0 to 45.6)100.0 (39.8 to 100.0)0 (0.0 to 26.5)
Fever: 38.0 to 38.4 deg C0 (0.0 to 20.6)6.3 (0.2 to 30.2)75.0 (19.4 to 99.4)0 (0.0 to 26.5)
Fever: >38.4 to 38.9 deg C6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
Fever: >38.9 to 40.0 deg C6.3 (0.2 to 30.2)6.3 (0.2 to 30.2)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fever: >40.0 deg C0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fatigue: Any68.8 (41.3 to 89.0)62.5 (35.4 to 84.8)100.0 (39.8 to 100.0)75.0 (42.8 to 94.5)
Fatigue: Mild43.8 (19.8 to 70.1)25.0 (7.3 to 52.4)25.0 (0.6 to 80.6)58.3 (27.7 to 84.8)
Fatigue: Moderate25.0 (7.3 to 52.4)37.5 (15.2 to 64.6)75.0 (19.4 to 99.4)16.7 (2.1 to 48.4)
Fatigue: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Fatigue: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Headache: Any50.0 (24.7 to 75.3)56.3 (29.9 to 80.2)75.0 (19.4 to 99.4)33.3 (9.9 to 65.1)
Headache: Mild25.0 (7.3 to 52.4)25.0 (7.3 to 52.4)25.0 (0.6 to 80.6)25.0 (5.5 to 57.2)
Headache: Moderate25.0 (7.3 to 52.4)31.3 (11.0 to 58.7)50.0 (6.8 to 93.2)8.3 (0.2 to 38.5)
Headache: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Headache: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Chills: Any31.3 (11.0 to 58.7)43.8 (19.8 to 70.1)75.0 (19.4 to 99.4)33.3 (9.9 to 65.1)
Chills: Mild25.0 (7.3 to 52.4)25.0 (7.3 to 52.4)75.0 (19.4 to 99.4)33.3 (9.9 to 65.1)
Chills: Moderate6.3 (0.2 to 30.2)18.8 (4.0 to 45.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Chills: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Chills: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Any0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Vomiting: Mild0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)8.3 (0.2 to 38.5)
Vomiting: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Vomiting: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Any6.3 (0.2 to 30.2)0 (0.0 to 20.6)50.0 (6.8 to 93.2)0 (0.0 to 26.5)
Diarrhea: Mild6.3 (0.2 to 30.2)0 (0.0 to 20.6)50.0 (6.8 to 93.2)0 (0.0 to 26.5)
Diarrhea: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
Diarrhea: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened muscle pain: Any0 (0.0 to 20.6)18.8 (4.0 to 45.6)50.0 (6.8 to 93.2)8.3 (0.2 to 38.5)
New or worsened muscle pain: Mild0 (0.0 to 20.6)18.8 (4.0 to 45.6)0 (0.0 to 60.2)8.3 (0.2 to 38.5)
New or worsened muscle pain: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)50.0 (6.8 to 93.2)0 (0.0 to 26.5)
New or worsened muscle pain: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened muscle pain: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened joint pain: Any0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
New or worsened joint pain: Mild0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened joint pain: Moderate0 (0.0 to 20.6)0 (0.0 to 20.6)25.0 (0.6 to 80.6)0 (0.0 to 26.5)
New or worsened joint pain: Severe0 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
New or worsened joint pain: Grade 40 (0.0 to 20.6)0 (0.0 to 20.6)0 (0.0 to 60.2)0 (0.0 to 26.5)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age
Percentage of participantsPhase 1: 5 to <12 Years BNT162b2 10 mcg
Fever:>=38.0 deg C2.6 (0.1 to 13.8)
Fever:38.0 to 38.4 deg C0 (0.0 to 9.3)
Fever: >38.4 to 38.9 deg C0 (0.0 to 9.3)
Fever: >38.9 to 40.0 deg C2.6 (0.1 to 13.8)
Fever: >40.0 deg C0 (0.0 to 9.3)
Fatigue: Any39.5 (24.0 to 56.6)
Fatigue: Mild21.1 (9.6 to 37.3)
Fatigue: Moderate15.8 (6.0 to 31.3)
Fatigue: Severe2.6 (0.1 to 13.8)
Fatigue: Grade 40 (0.0 to 9.3)
Headache: Any34.2 (19.6 to 51.4)
Headache: Mild21.1 (9.6 to 37.3)
Headache: Moderate10.5 (2.9 to 24.8)
Headache: Severe2.6 (0.1 to 13.8)
Headache: Grade 40 (0.0 to 9.3)
Chills: Any15.8 (6.0 to 31.3)
Chills: Mild13.2 (4.4 to 28.1)
Chills: Moderate2.6 (0.1 to 13.8)
Chills: Severe0 (0.0 to 9.3)
Chills: Grade 40 (0.0 to 9.3)
Vomiting: Any2.6 (0.1 to 13.8)
Vomiting: Mild2.6 (0.1 to 13.8)
Vomiting: Moderate0 (0.0 to 9.3)
Vomiting: Severe0 (0.0 to 9.3)
Vomiting: Grade 40 (0.0 to 9.3)
Diarrhea: Any0 (0.0 to 9.3)
Diarrhea: Mild0 (0.0 to 9.3)
Diarrhea: Moderate0 (0.0 to 9.3)
Diarrhea: Severe0 (0.0 to 9.3)
Diarrhea: Grade 40 (0.0 to 9.3)
New or worsened muscle pain: Any7.9 (1.7 to 21.4)
New or worsened muscle pain: Mild2.6 (0.1 to 13.8)
New or worsened muscle pain: Moderate5.3 (0.6 to 17.7)
New or worsened muscle pain: Severe0 (0.0 to 9.3)
New or worsened muscle pain: Grade 40 (0.0 to 9.3)
New or worsened joint pain: Any2.6 (0.1 to 13.8)
New or worsened joint pain: Mild0 (0.0 to 9.3)
New or worsened joint pain: Moderate2.6 (0.1 to 13.8)
New or worsened joint pain: Severe0 (0.0 to 9.3)
New or worsened joint pain: Grade 40 (0.0 to 9.3)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Redness: Any0 (0.0 to 20.6)28.1 (13.7 to 46.7)
Redness: Mild0 (0.0 to 20.6)25.0 (11.5 to 43.4)
Redness: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Redness: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Redness: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Swelling: Any0 (0.0 to 20.6)9.4 (2.0 to 25.0)
Swelling: Mild0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Swelling: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Swelling: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Swelling: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Pain at the injection site: Any31.3 (11.0 to 58.7)62.5 (43.7 to 78.9)
Pain at the injection site: Mild25.0 (7.3 to 52.4)56.3 (37.7 to 73.6)
Pain at the injection site: Moderate6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Pain at the injection site: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Pain at the injection site: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Redness: Any0 (0.0 to 20.6)15.6 (5.3 to 32.8)
Redness: Mild0 (0.0 to 20.6)15.6 (5.3 to 32.8)
Redness: Moderate0 (0.0 to 20.6)0 (0.0 to 10.9)
Redness: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Redness: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Swelling: Any0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Swelling: Mild0 (0.0 to 20.6)0 (0.0 to 10.9)
Swelling: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Swelling: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Swelling: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Pain at the injection site: Any37.5 (15.2 to 64.6)53.1 (34.7 to 70.9)
Pain at the injection site: Mild37.5 (15.2 to 64.6)43.8 (26.4 to 62.3)
Pain at the injection site: Moderate0 (0.0 to 20.6)9.4 (2.0 to 25.0)
Pain at the injection site: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Pain at the injection site: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
Redness: Any3.8 (0.1 to 19.6)15.4 (1.9 to 45.4)
Redness: Mild3.8 (0.1 to 19.6)15.4 (1.9 to 45.4)
Redness: Moderate0 (0.0 to 13.2)0 (0.0 to 24.7)
Redness: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Redness: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Swelling: Any0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Swelling: Mild0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Swelling: Moderate0 (0.0 to 13.2)0 (0.0 to 24.7)
Swelling: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Swelling: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Pain at the injection site: Any34.6 (17.2 to 55.7)84.6 (54.6 to 98.1)
Pain at the injection site: Mild34.6 (17.2 to 55.7)38.5 (13.9 to 68.4)
Pain at the injection site: Moderate0 (0.0 to 13.2)38.5 (13.9 to 68.4)
Pain at the injection site: Severe0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Pain at the injection site: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Fever: >=38.0 deg C0 (0.0 to 20.6)18.8 (7.2 to 36.4)
Fever: 38.0 to 38.4 deg C0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Fever: >38.4 to 38.9 deg C0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Fever: >38.9 to 40.0 deg C0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Fever: >40.0 deg C0 (0.0 to 20.6)0 (0.0 to 10.9)
Fatigue: Any25.0 (7.3 to 52.4)46.9 (29.1 to 65.3)
Fatigue: Mild18.8 (4.0 to 45.6)34.4 (18.6 to 53.2)
Fatigue: Moderate6.3 (0.2 to 30.2)12.5 (3.5 to 29.0)
Fatigue: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Fatigue: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Headache: Any12.5 (1.6 to 38.3)9.4 (2.0 to 25.0)
Headache: Mild6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Headache: Moderate6.3 (0.2 to 30.2)3.1 (0.1 to 16.2)
Headache: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Headache: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Chills: Any6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Chills: Mild0 (0.0 to 20.6)0 (0.0 to 10.9)
Chills: Moderate6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Chills: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Chills: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Vomiting: Any0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Vomiting: Mild0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Vomiting: Moderate0 (0.0 to 20.6)0 (0.0 to 10.9)
Vomiting: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Vomiting: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Any6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Diarrhea: Mild6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Diarrhea: Moderate0 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened muscle pain: Any0 (0.0 to 20.6)6.3 (0.8 to 20.8)
New or worsened muscle pain: Mild0 (0.0 to 20.6)3.1 (0.1 to 16.2)
New or worsened muscle pain: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
New or worsened muscle pain: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened muscle pain: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Any6.3 (0.2 to 30.2)0 (0.0 to 10.9)
New or worsened joint pain: Mild0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Moderate6.3 (0.2 to 30.2)0 (0.0 to 10.9)
New or worsened joint pain: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Fever: >=38.0 deg C6.3 (0.2 to 30.2)18.8 (7.2 to 36.4)
Fever: 38.0 to 38.4 deg C0 (0.0 to 20.6)9.4 (2.0 to 25.0)
Fever: >38.4 to 38.9 deg C6.3 (0.2 to 30.2)3.1 (0.1 to 16.2)
Fever: >38.9 to 40.0 deg C0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Fever: >40.0 deg C0 (0.0 to 20.6)0 (0.0 to 10.9)
Fatigue: Any25.0 (7.3 to 52.4)59.4 (40.6 to 76.3)
Fatigue: Mild12.5 (1.6 to 38.3)31.3 (16.1 to 50.0)
Fatigue: Moderate12.5 (1.6 to 38.3)28.1 (13.7 to 46.7)
Fatigue: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Fatigue: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Headache: Any12.5 (1.6 to 38.3)15.6 (5.3 to 32.8)
Headache: Mild6.3 (0.2 to 30.2)9.4 (2.0 to 25.0)
Headache: Moderate6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Headache: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Headache: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Chills: Any6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Chills: Mild0 (0.0 to 20.6)6.3 (0.8 to 20.8)
Chills: Moderate6.3 (0.2 to 30.2)0 (0.0 to 10.9)
Chills: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Chills: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Vomiting: Any6.3 (0.2 to 30.2)6.3 (0.8 to 20.8)
Vomiting: Mild6.3 (0.2 to 30.2)3.1 (0.1 to 16.2)
Vomiting: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
Vomiting: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Vomiting: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Any6.3 (0.2 to 30.2)12.5 (3.5 to 29.0)
Diarrhea: Mild6.3 (0.2 to 30.2)12.5 (3.5 to 29.0)
Diarrhea: Moderate0 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
Diarrhea: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened muscle pain: Any0 (0.0 to 20.6)9.4 (2.0 to 25.0)
New or worsened muscle pain: Mild0 (0.0 to 20.6)6.3 (0.8 to 20.8)
New or worsened muscle pain: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
New or worsened muscle pain: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened muscle pain: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Any0 (0.0 to 20.6)3.1 (0.1 to 16.2)
New or worsened joint pain: Mild0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Moderate0 (0.0 to 20.6)3.1 (0.1 to 16.2)
New or worsened joint pain: Severe0 (0.0 to 20.6)0 (0.0 to 10.9)
New or worsened joint pain: Grade 40 (0.0 to 20.6)0 (0.0 to 10.9)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
Fever: >=38.0 deg C0 (0.0 to 13.2)15.4 (1.9 to 45.4)
Fever: 38.0 to 38.4 deg C0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Fever: >38.4 to 38.9 deg C0 (0.0 to 13.2)0 (0.0 to 24.7)
Fever: >38.9 to 40.0 deg C0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Fever: >40.0 deg C0 (0.0 to 13.2)0 (0.0 to 24.7)
Fatigue: Any30.8 (14.3 to 51.8)53.8 (25.1 to 80.8)
Fatigue: Mild19.2 (6.6 to 39.4)23.1 (5.0 to 53.8)
Fatigue: Moderate11.5 (2.4 to 30.2)30.8 (9.1 to 61.4)
Fatigue: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Fatigue: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Headache: Any3.8 (0.1 to 19.6)23.1 (5.0 to 53.8)
Headache: Mild3.8 (0.1 to 19.6)15.4 (1.9 to 45.4)
Headache: Moderate0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Headache: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Headache: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Chills: Any0 (0.0 to 13.2)15.4 (1.9 to 45.4)
Chills: Mild0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Chills: Moderate0 (0.0 to 13.2)7.7 (0.2 to 36.0)
Chills: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Chills: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Vomiting: Any0 (0.0 to 13.2)23.1 (5.0 to 53.8)
Vomiting: Mild0 (0.0 to 13.2)0 (0.0 to 24.7)
Vomiting: Moderate0 (0.0 to 13.2)23.1 (5.0 to 53.8)
Vomiting: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Vomiting: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
Diarrhea: Any3.8 (0.1 to 19.6)7.7 (0.2 to 36.0)
Diarrhea: Mild3.8 (0.1 to 19.6)7.7 (0.2 to 36.0)
Diarrhea: Moderate0 (0.0 to 13.2)0 (0.0 to 24.7)
Diarrhea: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
Diarrhea: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
New or worsened muscle pain: Any0 (0.0 to 13.2)15.4 (1.9 to 45.4)
New or worsened muscle pain: Mild0 (0.0 to 13.2)7.7 (0.2 to 36.0)
New or worsened muscle pain: Moderate0 (0.0 to 13.2)7.7 (0.2 to 36.0)
New or worsened muscle pain: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
New or worsened muscle pain: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
New or worsened joint pain: Any0 (0.0 to 13.2)7.7 (0.2 to 36.0)
New or worsened joint pain: Mild0 (0.0 to 13.2)7.7 (0.2 to 36.0)
New or worsened joint pain: Moderate0 (0.0 to 13.2)0 (0.0 to 24.7)
New or worsened joint pain: Severe0 (0.0 to 13.2)0 (0.0 to 24.7)
New or worsened joint pain: Grade 40 (0.0 to 13.2)0 (0.0 to 24.7)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Redness: Any18.8 (4.0 to 45.6)
Redness: Mild18.8 (4.0 to 45.6)
Redness: Moderate0 (0.0 to 20.6)
Redness: Severe0 (0.0 to 20.6)
Redness: Grade 40 (0.0 to 20.6)
Swelling: Any6.3 (0.2 to 30.2)
Swelling: Mild6.3 (0.2 to 30.2)
Swelling: Moderate0 (0.0 to 20.6)
Swelling: Severe0 (0.0 to 20.6)
Swelling: Grade 40 (0.0 to 20.6)
Tenderness at the injection site: Any0 (0.0 to 20.6)
Tenderness at the injection site: Mild0 (0.0 to 20.6)
Tenderness at the injection site: Moderate0 (0.0 to 20.6)
Tenderness at the injection site: Severe0 (0.0 to 20.6)
Tenderness at the injection site: Grade 40 (0.0 to 20.6)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Redness: Any0 (0.0 to 20.6)
Redness: Mild0 (0.0 to 20.6)
Redness: Moderate0 (0.0 to 20.6)
Redness: Severe0 (0.0 to 20.6)
Redness: Grade 40 (0.0 to 20.6)
Swelling: Any0 (0.0 to 20.6)
Swelling: Mild0 (0.0 to 20.6)
Swelling: Moderate0 (0.0 to 20.6)
Swelling: Severe0 (0.0 to 20.6)
Swelling: Grade 40 (0.0 to 20.6)
Tenderness at the injection site: Any6.3 (0.2 to 30.2)
Tenderness at the injection site: Mild6.3 (0.2 to 30.2)
Tenderness at the injection site: Moderate0 (0.0 to 20.6)
Tenderness at the injection site: Severe0 (0.0 to 20.6)
Tenderness at the injection site: Grade 40 (0.0 to 20.6)
PrimaryPhase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Redness: Any13.3 (1.7 to 40.5)
Redness: Mild13.3 (1.7 to 40.5)
Redness: Moderate0 (0.0 to 21.8)
Redness: Severe0 (0.0 to 21.8)
Redness: Grade 40 (0.0 to 21.8)
Swelling: Any6.7 (0.2 to 31.9)
Swelling: Mild6.7 (0.2 to 31.9)
Swelling: Moderate0 (0.0 to 21.8)
Swelling: Severe0 (0.0 to 21.8)
Swelling: Grade 40 (0.0 to 21.8)
Tenderness at the injection site: Any26.7 (7.8 to 55.1)
Tenderness at the injection site: Mild26.7 (7.8 to 55.1)
Tenderness at the injection site: Moderate0 (0.0 to 21.8)
Tenderness at the injection site: Severe0 (0.0 to 21.8)
Tenderness at the injection site: Grade 40 (0.0 to 21.8)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Fever: >=38.0 deg C6.3 (0.2 to 30.2)
Fever: 38.0 to 38.4 deg C6.3 (0.2 to 30.2)
Fever: >38.4 to 38.9 deg C0 (0.0 to 20.6)
Fever: >38.9 to 40.0 deg C0 (0.0 to 20.6)
Fever: >40.0 deg C0 (0.0 to 20.6)
Decreased appetite: Any6.3 (0.2 to 30.2)
Decreased appetite: Mild0 (0.0 to 20.6)
Decreased appetite: Moderate6.3 (0.2 to 30.2)
Decreased appetite: Severe0 (0.0 to 20.6)
Decreased appetite: Grade 40 (0.0 to 20.6)
Drowsiness: Any25.0 (7.3 to 52.4)
Drowsiness: Mild18.8 (4.0 to 45.6)
Drowsiness: Moderate6.3 (0.2 to 30.2)
Drowsiness: Severe0 (0.0 to 20.6)
Drowsiness: Grade 40 (0.0 to 20.6)
Irritability: Any43.8 (19.8 to 70.1)
Irritability: Mild18.8 (4.0 to 45.6)
Irritability: Moderate25.0 (7.3 to 52.4)
Irritability: Severe0 (0.0 to 20.6)
Irritability: Grade 40 (0.0 to 20.6)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Fever: >=38.0 deg C12.5 (1.6 to 38.3)
Fever: 38.0 to 38.4 deg C12.5 (1.6 to 38.3)
Fever: >38.4 to 38.9 deg C0 (0.0 to 20.6)
Fever: >38.9 to 40.0 deg C0 (0.0 to 20.6)
Fever: >40.0 deg C0 (0.0 to 20.6)
Decreased appetite: Any12.5 (1.6 to 38.3)
Decreased appetite: Mild12.5 (1.6 to 38.3)
Decreased appetite: Moderate0 (0.0 to 20.6)
Decreased appetite: Severe0 (0.0 to 20.6)
Decreased appetite: Grade 40 (0.0 to 20.6)
Drowsiness: Any6.3 (0.2 to 30.2)
Drowsiness: Mild6.3 (0.2 to 30.2)
Drowsiness: Moderate0 (0.0 to 20.6)
Drowsiness: Severe0 (0.0 to 20.6)
Drowsiness: Grade 40 (0.0 to 20.6)
Irritability: Any31.3 (11.0 to 58.7)
Irritability: Mild31.3 (11.0 to 58.7)
Irritability: Moderate0 (0.0 to 20.6)
Irritability: Severe0 (0.0 to 20.6)
Irritability: Grade 40 (0.0 to 20.6)
PrimaryPhase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 1: Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Fever: >=38.0 deg C6.7 (0.2 to 31.9)
Fever: 38.0 to 38.4 deg C0 (0.0 to 21.8)
Fever: >38.4 to 38.9 deg C0 (0.0 to 21.8)
Fever: >38.9 to 40.0 deg C6.7 (0.2 to 31.9)
Fever: >40.0 deg C0 (0.0 to 21.8)
Decreased appetite: Any13.3 (1.7 to 40.5)
Decreased appetite: Mild6.7 (0.2 to 31.9)
Decreased appetite: Moderate6.7 (0.2 to 31.9)
Decreased appetite: Severe0 (0.0 to 21.8)
Decreased appetite: Grade 40 (0.0 to 21.8)
Drowsiness: Any6.7 (0.2 to 31.9)
Drowsiness: Mild0 (0.0 to 21.8)
Drowsiness: Moderate6.7 (0.2 to 31.9)
Drowsiness: Severe0 (0.0 to 21.8)
Drowsiness: Grade 40 (0.0 to 21.8)
Irritability: Any26.7 (7.8 to 55.1)
Irritability: Mild13.3 (1.7 to 40.5)
Irritability: Moderate13.3 (1.7 to 40.5)
Irritability: Severe0 (0.0 to 21.8)
Irritability: Grade 40 (0.0 to 21.8)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 1: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age43.8 (19.8 to 70.1)31.3 (11.0 to 58.7)50.0 (6.8 to 93.2)25.0 (5.5 to 57.2)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 1: 5 to <12 Years BNT162b2 10 mcg
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age15.8 (6.0 to 31.3)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 1: 5 to <12 Years BNT162b2 10 mcg
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age0 (0 to 0)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 1: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age25.0 (7.3 to 52.4)37.5 (21.1 to 56.3)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 1: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age11.1 (2.4 to 29.2)0 (0.0 to 24.7)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age0 (0.0 to 20.6)0 (0.0 to 10.9)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age0 (0 to 12.8)0 (0 to 24.7)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 1: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age12.5 (1.6 to 38.3)
PrimaryPhase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 1: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age6.7 (0.2 to 31.9)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age0 (0 to 20.6)
PrimaryPhase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.

Time frame:
Phase 1: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age0 (0 to 21.8)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Redness: Any15.5 (12.5 to 19.0)6.2 (3.6 to 9.8)
Redness: Mild11.8 (9.2 to 15.0)5.4 (3.0 to 8.9)
Redness: Moderate3.7 (2.2 to 5.7)0.4 (0.0 to 2.1)
Redness: Severe0 (0.0 to 0.7)0.4 (0.0 to 2.1)
Redness: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Swelling: Any10.9 (8.3 to 13.9)4.6 (2.4 to 7.9)
Swelling: Mild7.6 (5.4 to 10.2)2.7 (1.1 to 5.5)
Swelling: Moderate3.3 (1.9 to 5.2)1.9 (0.6 to 4.4)
Swelling: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
Swelling: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Pain at the injection site: Any72.4 (68.3 to 76.2)28.1 (22.7 to 34.0)
Pain at the injection site: Mild57.7 (53.3 to 62.0)23.5 (18.4 to 29.1)
Pain at the injection site: Moderate14.8 (11.8 to 18.1)4.6 (2.4 to 7.9)
Pain at the injection site: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
Pain at the injection site: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Redness: Any2.1 (1.0 to 3.8)
Redness: Mild1.5 (0.6 to 3.0)
Redness: Moderate0.6 (0.1 to 1.8)
Redness: Severe0 (0.0 to 0.8)
Redness: Grade 40 (0.0 to 0.8)
Swelling: Any4.4 (2.8 to 6.7)
Swelling: Mild2.7 (1.5 to 4.6)
Swelling: Moderate1.7 (0.7 to 3.3)
Swelling: Severe0 (0.0 to 0.8)
Swelling: Grade 40 (0.0 to 0.8)
Pain at the injection site: Any72.4 (68.2 to 76.4)
Pain at the injection site: Mild43.8 (39.3 to 48.4)
Pain at the injection site: Moderate28.2 (24.2 to 32.5)
Pain at the injection site: Severe0.4 (0.1 to 1.5)
Pain at the injection site: Grade 40 (0.0 to 0.8)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Redness: Any16.7 (13.5 to 20.3)1.9 (0.2 to 6.6)
Redness: Mild9.9 (7.4 to 12.8)1.9 (0.2 to 6.6)
Redness: Moderate6.8 (4.8 to 9.4)0 (0.0 to 3.4)
Redness: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
Redness: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Swelling: Any11.5 (8.8 to 14.6)4.7 (1.5 to 10.6)
Swelling: Mild6.8 (4.8 to 9.4)2.8 (0.6 to 8.0)
Swelling: Moderate4.6 (3.0 to 6.9)1.9 (0.2 to 6.6)
Swelling: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
Swelling: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Pain at the injection site: Any66.8 (62.5 to 70.9)23.4 (15.7 to 32.5)
Pain at the injection site: Mild48.3 (43.8 to 52.8)19.6 (12.6 to 28.4)
Pain at the injection site: Moderate18.5 (15.2 to 22.2)3.7 (1.0 to 9.3)
Pain at the injection site: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
Pain at the injection site: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm),moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Redness: Any0.9 (0.2 to 2.3)
Redness: Mild0.4 (0.1 to 1.6)
Redness: Moderate0.2 (0.0 to 1.2)
Redness: Severe0.2 (0.0 to 1.2)
Redness: Grade 40 (0.0 to 0.8)
Swelling: Any1.8 (0.8 to 3.5)
Swelling: Mild0.9 (0.2 to 2.3)
Swelling: Moderate0.9 (0.2 to 2.3)
Swelling: Severe0 (0.0 to 0.8)
Swelling: Grade 40 (0.0 to 0.8)
Pain at the injection site: Any57.8 (53.1 to 62.4)
Pain at the injection site: Mild36.6 (32.1 to 41.3)
Pain at the injection site: Moderate20.8 (17.1 to 24.8)
Pain at the injection site: Severe0.4 (0.1 to 1.6)
Pain at the injection site: Grade 40 (0.0 to 0.8)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age
Redness: Any17.0 (13.4 to 21.1)
Redness: Mild11.2 (8.2 to 14.7)
Redness: Moderate5.8 (3.7 to 8.6)
Redness: Severe0 (0.0 to 0.9)
Redness: Grade 40 (0.0 to 0.9)
Swelling: Any12.7 (9.6 to 16.4)
Swelling: Mild9.4 (6.7 to 12.7)
Swelling: Moderate3.3 (1.8 to 5.6)
Swelling: Severe0 (0.0 to 0.9)
Swelling: Grade 40 (0.0 to 0.9)
Pain at the injection site: Any69.3 (64.5 to 73.8)
Pain at the injection site: Mild48.0 (42.9 to 53.0)
Pain at the injection site: Moderate20.8 (16.9 to 25.2)
Pain at the injection site: Severe0.5 (0.1 to 1.8)
Pain at the injection site: Grade 40 (0.0 to 0.9)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Redness: Any3.5 (1.9 to 5.7)
Redness: Mild3.0 (1.5 to 5.1)
Redness: Moderate0.5 (0.1 to 1.8)
Redness: Severe0 (0.0 to 0.9)
Redness: Grade 40 (0.0 to 0.9)
Swelling: Any3.0 (1.5 to 5.1)
Swelling: Mild2.0 (0.9 to 3.9)
Swelling: Moderate1.0 (0.3 to 2.5)
Swelling: Severe0 (0.0 to 0.9)
Swelling: Grade 40 (0.0 to 0.9)
Pain at the injection site: Any63.5 (58.6 to 68.2)
Pain at the injection site: Mild35.8 (31.1 to 40.7)
Pain at the injection site: Moderate27.4 (23.1 to 32.0)
Pain at the injection site: Severe0.2 (0.0 to 1.4)
Pain at the injection site: Grade 40 (0.0 to 0.9)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Fever: >= 38.0 deg C1.4 (0.5 to 2.8)3.1 (1.3 to 6.0)
Fever: 38.0 to 38.4 deg C0.8 (0.2 to 2.0)1.9 (0.6 to 4.4)
Fever: >38.4 to 38.9 deg C0.6 (0.1 to 1.7)1.2 (0.2 to 3.3)
Fever: >38.9 to 40.0 deg C0 (0.0 to 0.7)0 (0.0 to 1.4)
Fever: >40.0 deg C0 (0.0 to 0.7)0 (0.0 to 1.4)
Fatigue: Any37.1 (32.9 to 41.4)37.7 (31.8 to 43.9)
Fatigue: Mild24.1 (20.4 to 28.0)23.8 (18.8 to 29.5)
Fatigue: Moderate13.0 (10.2 to 16.2)13.1 (9.2 to 17.8)
Fatigue: Severe0 (0.0 to 0.7)0.8 (0.1 to 2.8)
Fatigue: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Headache: Any25.4 (21.7 to 29.4)25.8 (20.6 to 31.5)
Headache: Mild18.3 (15.0 to 21.9)19.2 (14.6 to 24.6)
Headache: Moderate6.8 (4.8 to 9.3)6.5 (3.9 to 10.3)
Headache: Severe0.4 (0.0 to 1.4)0 (0.0 to 1.4)
Headache: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Chills: Any7.2 (5.1 to 9.8)9.6 (6.3 to 13.9)
Chills: Mild5.6 (3.8 to 8.0)6.5 (3.9 to 10.3)
Chills: Moderate1.4 (0.5 to 2.8)3.1 (1.3 to 6.0)
Chills: Severe0.2 (0.0 to 1.1)0 (0.0 to 1.4)
Chills: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Vomiting: Any1.7 (0.8 to 3.3)2.3 (0.9 to 5.0)
Vomiting: Mild1.6 (0.7 to 3.0)1.9 (0.6 to 4.4)
Vomiting: Moderate0.2 (0.0 to 1.1)0.4 (0.0 to 2.1)
Vomiting: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
Vomiting: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
Diarrhea: Any6.2 (4.3 to 8.7)8.5 (5.4 to 12.5)
Diarrhea: Mild6.0 (4.1 to 8.4)8.1 (5.1 to 12.1)
Diarrhea: Moderate0.2 (0.0 to 1.1)0.4 (0.0 to 2.1)
Diarrhea: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
Diarrhea: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
New or worsened muscle pain: Any11.7 (9.0 to 14.7)10.0 (6.6 to 14.3)
New or worsened muscle pain: Mild8.2 (5.9 to 10.9)7.7 (4.8 to 11.6)
New or worsened muscle pain: Moderate3.5 (2.1 to 5.5)2.3 (0.9 to 5.0)
New or worsened muscle pain: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
New or worsened muscle pain: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
New or worsened joint pain: Any5.2 (3.5 to 7.5)6.9 (4.2 to 10.7)
New or worsened joint pain: Mild4.5 (2.9 to 6.6)5.4 (3.0 to 8.9)
New or worsened joint pain: Moderate0.8 (0.2 to 2.0)1.5 (0.4 to 3.9)
New or worsened joint pain: Severe0 (0.0 to 0.7)0 (0.0 to 1.4)
New or worsened joint pain: Grade 40 (0.0 to 0.7)0 (0.0 to 1.4)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Fever:>=38.0 deg C4.2 (2.6 to 6.4)
Fever: 8.0 to 38.4 deg C2.3 (1.2 to 4.1)
Fever: >38.4 to 38.9 deg C1.3 (0.5 to 2.7)
Fever: >38.9 to 40.0 deg C0.6 (0.1 to 1.8)
Fever: >40.0 deg C0 (0.0 to 0.8)
Fatigue: Any42.3 (37.8 to 46.9)
Fatigue: Mild26.3 (22.4 to 30.5)
Fatigue: Moderate15.6 (12.4 to 19.2)
Fatigue: Severe0.4 (0.1 to 1.5)
Fatigue: Grade 40 (0.0 to 0.8)
Headache: Any33.3 (29.0 to 37.7)
Headache: Mild22.9 (19.2 to 27.0)
Headache: Moderate10.3 (7.7 to 13.4)
Headache: Severe0 (0.0 to 0.8)
Headache: Grade 40 (0.0 to 0.8)
Chills: Any11.4 (8.7 to 14.6)
Chills: Mild8.6 (6.3 to 11.5)
Chills: Moderate2.5 (1.3 to 4.4)
Chills: Severe0.2 (0.0 to 1.2)
Chills: Grade 40 (0.0 to 0.8)
Vomiting: Any2.9 (1.6 to 4.9)
Vomiting: Mild2.7 (1.5 to 4.6)
Vomiting: Moderate0.2 (0.0 to 1.2)
Vomiting: Severe0 (0.0 to 0.8)
Vomiting: Grade 40 (0.0 to 0.8)
Diarrhea: Any9.1 (6.6 to 12.0)
Diarrhea: Mild6.9 (4.8 to 9.6)
Diarrhea: Moderate2.1 (1.0 to 3.8)
Diarrhea: Severe0 (0.0 to 0.8)
Diarrhea: Grade 40 (0.0 to 0.8)
New or worsened muscle pain: Any26.3 (22.4 to 30.5)
New or worsened muscle pain: Mild14.7 (11.7 to 18.2)
New or worsened muscle pain: Moderate10.9 (8.3 to 14.1)
New or worsened muscle pain: Severe0.6 (0.1 to 1.8)
New or worsened muscle pain: Grade 40 (0.0 to 0.8)
New or worsened joint pain: Any10.5 (7.9 to 13.6)
New or worsened joint pain: Mild5.1 (3.3 to 7.4)
New or worsened joint pain: Moderate5.5 (3.6 to 7.9)
New or worsened joint pain: Severe0 (0.0 to 0.8)
New or worsened joint pain: Grade 40 (0.0 to 0.8)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Fever: >=38.05.0 (3.3 to 7.3)0 (0.0 to 3.4)
Fever:38.0 to 38.4 deg C2.2 (1.1 to 3.9)0 (0.0 to 3.4)
Fever: >38.4 to 38.9 deg C1.8 (0.8 to 3.4)0 (0.0 to 3.4)
Fever: >38.9 to 40.0 deg C1.0 (0.3 to 2.3)0 (0.0 to 3.4)
Fever: >40.0 deg C0 (0.0 to 0.7)0 (0.0 to 3.4)
Fatigue: Any38.2 (33.9 to 42.7)29.0 (20.6 to 38.5)
Fatigue: Mild22.5 (18.9 to 26.5)15.9 (9.5 to 24.2)
Fatigue: Moderate15.5 (12.4 to 19.0)13.1 (7.3 to 21.0)
Fatigue: Severe0.2 (0.0 to 1.1)0 (0.0 to 3.4)
Fatigue: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Headache: Any30.2 (26.2 to 34.4)20.6 (13.4 to 29.5)
Headache: Mild20.1 (16.7 to 23.9)14.0 (8.1 to 22.1)
Headache: Moderate9.9 (7.4 to 12.8)6.5 (2.7 to 13.0)
Headache: Severe0.2 (0.0 to 1.1)0 (0.0 to 3.4)
Headache: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Chills: Any9.1 (6.7 to 11.9)7.5 (3.3 to 14.2)
Chills: Mild5.8 (3.9 to 8.3)6.5 (2.7 to 13.0)
Chills: Moderate3.2 (1.9 to 5.2)0.9 (0.0 to 5.1)
Chills: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
Chills: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Vomiting: Any2.0 (1.0 to 3.7)3.7 (1.0 to 9.3)
Vomiting: Mild1.8 (0.8 to 3.4)2.8 (0.6 to 8.0)
Vomiting: Moderate0.2 (0.0 to 1.1)0.9 (0.0 to 5.1)
Vomiting: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
Vomiting: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
Diarrhea: Any7.4 (5.3 to 10.1)5.6 (2.1 to 11.8)
Diarrhea: Mild7.0 (5.0 to 9.7)5.6 (2.1 to 11.8)
Diarrhea: Moderate0.2 (0.0 to 1.1)0 (0.0 to 3.4)
Diarrhea: Severe0.2 (0.0 to 1.1)0 (0.0 to 3.4)
Diarrhea: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
New or worsened muscle pain: Any14.7 (11.7 to 18.1)11.2 (5.9 to 18.8)
New or worsened muscle pain: Mild9.3 (6.9 to 12.2)9.3 (4.6 to 16.5)
New or worsened muscle pain: Moderate5.4 (3.6 to 7.8)1.9 (0.2 to 6.6)
New or worsened muscle pain: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
New or worsened muscle pain: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
New or worsened joint pain: Any6.4 (4.4 to 9.0)6.5 (2.7 to 13.0)
New or worsened joint pain: Mild4.2 (2.6 to 6.4)6.5 (2.7 to 13.0)
New or worsened joint pain: Moderate2.2 (1.1 to 3.9)0 (0.0 to 3.4)
New or worsened joint pain: Severe0 (0.0 to 0.7)0 (0.0 to 3.4)
New or worsened joint pain: Grade 40 (0.0 to 0.7)0 (0.0 to 3.4)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Fever: >=38.0 deg C3.3 (1.9 to 5.5)
Fever:38.0 to 38.4 deg C1.6 (0.6 to 3.2)
Fever: >38.4 to 38.9 deg C1.3 (0.5 to 2.9)
Fever: >38.9 to 40.0 deg C0.4 (0.1 to 1.6)
Fever: >40.0 deg C0 (0.0 to 0.8)
Fatigue: Any36.4 (31.9 to 41.0)
Fatigue: Mild21.0 (17.3 to 25.1)
Fatigue: Moderate15.0 (11.8 to 18.6)
Fatigue: Severe0.4 (0.1 to 1.6)
Fatigue: Grade 40 (0.0 to 0.8)
Headache: Any33.3 (28.9 to 37.8)
Headache: Mild19.4 (15.9 to 23.4)
Headache: Moderate13.2 (10.2 to 16.7)
Headache: Severe0.7 (0.1 to 1.9)
Headache: Grade 40 (0.0 to 0.8)
Chills: Any11.2 (8.4 to 14.4)
Chills: Mild7.4 (5.1 to 10.2)
Chills: Moderate3.8 (2.2 to 6.0)
Chills: Severe0 (0.0 to 0.8)
Chills: Grade 40 (0.0 to 0.8)
Vomiting: Any2.2 (1.1 to 4.1)
Vomiting: Mild2.0 (0.9 to 3.8)
Vomiting: Moderate0.2 (0.0 to 1.2)
Vomiting: Severe0 (0.0 to 0.8)
Vomiting: Grade 40 (0.0 to 0.8)
Diarrhea: Any7.1 (4.9 to 9.9)
Diarrhea: Mild5.1 (3.3 to 7.6)
Diarrhea: Moderate1.8 (0.8 to 3.5)
Diarrhea: Severe0.2 (0.0 to 1.2)
Diarrhea: Grade 40 (0.0 to 0.8)
New or worsened muscle pain: Any19.6 (16.1 to 23.6)
New or worsened muscle pain: Mild12.5 (9.6 to 15.9)
New or worsened muscle pain: Moderate6.9 (4.7 to 9.7)
New or worsened muscle pain: Severe0.2 (0.0 to 1.2)
New or worsened muscle pain: Grade 40 (0.0 to 0.8)
New or worsened joint pain: Any6.7 (4.6 to 9.4)
New or worsened joint pain: Mild3.8 (2.2 to 6.0)
New or worsened joint pain: Moderate2.7 (1.4 to 4.6)
New or worsened joint pain: Severe0.2 (0.0 to 1.2)
New or worsened joint pain: Grade 40 (0.0 to 0.8)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Fever: >=38.0 deg C4.6 (2.7 to 7.1)—
Fever:38.0 to 38.4 deg C2.5 (1.2 to 4.6)—
Fever: >38.4 to 38.9 deg C1.0 (0.3 to 2.6)—
Fever: >38.9 to 40.0 deg C1.0 (0.3 to 2.6)—
Fever: >40.0 deg C0 (0.0 to 0.9)—
Fatigue: Any38.8 (34.0 to 43.8)—
Fatigue: Mild26.4 (22.1 to 31.0)—
Fatigue: Moderate11.9 (8.9 to 15.5)—
Fatigue: Severe0.5 (0.1 to 1.8)—
Fatigue: Grade 40 (0.0 to 0.9)—
Headache: Any23.6 (19.5 to 28.1)—
Headache: Mild16.2 (12.7 to 20.3)—
Headache: Moderate6.9 (4.6 to 9.8)—
Headache: Severe0.5 (0.1 to 1.8)—
Headache: Grade 40 (0.0 to 0.9)—
Chills: Any8.9 (6.3 to 12.1)—
Chills: Mild5.8 (3.7 to 8.6)—
Chills: Moderate2.8 (1.4 to 4.9)—
Chills: Severe0.3 (0.0 to 1.4)—
Chills: Grade 40 (0.0 to 0.9)—
Vomiting: Any1.8 (0.7 to 3.6)—
Vomiting: Mild1.5 (0.6 to 3.3)—
Vomiting: Moderate0.3 (0.0 to 1.4)—
Vomiting: Severe0 (0.0 to 0.9)—
Vomiting: Grade 40 (0.0 to 0.9)—
Diarrhea: Any4.8 (2.9 to 7.4)—
Diarrhea: Mild4.6 (2.7 to 7.1)—
Diarrhea: Moderate0.3 (0.0 to 1.4)—
Diarrhea: Severe0 (0.0 to 0.9)—
Diarrhea: Grade 40 (0.0 to 0.9)—
New or worsened muscle pain: Any18.5 (14.8 to 22.7)—
New or worsened muscle pain: Mild10.2 (7.4 to 13.6)—
New or worsened muscle pain: Moderate8.4 (5.8 to 11.6)—
New or worsened muscle pain: Severe0 (0.0 to 0.9)—
New or worsened muscle pain: Grade 40 (0.0 to 0.9)—
New or worsened joint pain: Any5.8 (3.7 to 8.6)—
New or worsened joint pain: Mild4.1 (2.3 to 6.5)—
New or worsened joint pain: Moderate1.8 (0.7 to 3.6)—
New or worsened joint pain: Severe0 (0.0 to 0.9)—
New or worsened joint pain: Grade 40 (0.0 to 0.9)—
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Fever: >=38.0 deg C3.5 (1.9 to 5.7)
Fever: 8.0 to 38.4 deg C1.7 (0.7 to 3.5)
Fever: >38.4 to 38.9 deg C1.2 (0.4 to 2.9)
Fever: >38.9 to 40.0 deg C0.5 (0.1 to 1.8)
Fever: >40.0 deg C0 (0.0 to 0.9)
Fatigue: Any36.8 (32.1 to 41.7)
Fatigue: Mild21.7 (17.8 to 26.1)
Fatigue: Moderate14.8 (11.5 to 18.7)
Fatigue: Severe0.2 (0.0 to 1.4)
Fatigue: Grade 40 (0.0 to 0.9)
Headache: Any35.3 (30.7 to 40.2)
Headache: Mild23.0 (19.0 to 27.4)
Headache: Moderate11.6 (8.7 to 15.1)
Headache: Severe0.7 (0.2 to 2.1)
Headache: Grade 40 (0.0 to 0.9)
Chills: Any12.8 (9.7 to 16.5)
Chills: Mild8.4 (5.9 to 11.5)
Chills: Moderate4.4 (2.7 to 6.9)
Chills: Severe0 (0.0 to 0.9)
Chills: Grade 40 (0.0 to 0.9)
Vomiting: Any2.7 (1.4 to 4.8)
Vomiting: Mild2.2 (1.0 to 4.2)
Vomiting: Moderate0.5 (0.1 to 1.8)
Vomiting: Severe0 (0.0 to 0.9)
Vomiting: Grade 40 (0.0 to 0.9)
Diarrhea: Any4.4 (2.7 to 6.9)
Diarrhea: Mild4.0 (2.3 to 6.3)
Diarrhea: Moderate0.5 (0.1 to 1.8)
Diarrhea: Severe0 (0.0 to 0.9)
Diarrhea: Grade 40 (0.0 to 0.9)
New or worsened muscle pain: Any18.8 (15.1 to 22.9)
New or worsened muscle pain: Mild10.6 (7.8 to 14.0)
New or worsened muscle pain: Moderate8.1 (5.7 to 11.3)
New or worsened muscle pain: Severe0 (0.0 to 0.9)
New or worsened muscle pain: Grade 40 (0.0 to 0.9)
New or worsened joint pain: Any6.4 (4.2 to 9.3)
New or worsened joint pain: Mild4.0 (2.3 to 6.3)
New or worsened joint pain: Moderate2.5 (1.2 to 4.5)
New or worsened joint pain: Severe0 (0.0 to 0.9)
New or worsened joint pain: Grade 40 (0.0 to 0.9)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age7.1 (5.1 to 9.7)8.1 (5.1 to 12.1)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age5.3 (3.5 to 7.7)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age11.5 (8.6 to 14.9)—
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age1.4 (0.5 to 3.0)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age0.2 (0.0 to 1.1)0 (0.0 to 1.4)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age0.4 (0.0 to 1.5)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: Troponin Group: BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age0.5 (0.1 to 1.7)—
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age
Percentage of participantsPhase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age0 (0 to 0.8)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Redness: Any14.0 (12.8 to 15.3)5.9 (4.8 to 7.2)
Redness: Mild9.3 (8.3 to 10.3)5.1 (4.0 to 6.3)
Redness: Moderate4.7 (4.0 to 5.5)0.7 (0.4 to 1.3)
Redness: Severe0.0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Redness: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Swelling: Any10.3 (9.3 to 11.5)3.0 (2.2 to 4.0)
Swelling: Mild5.7 (4.9 to 6.6)1.8 (1.2 to 2.6)
Swelling: Moderate4.6 (3.9 to 5.4)1.2 (0.7 to 1.9)
Swelling: Severe0.0 (0.0 to 0.2)0 (0.0 to 0.2)
Swelling: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Pain at the injection site: Any72.9 (71.3 to 74.5)31.5 (29.2 to 33.9)
Pain at the injection site: Mild58.5 (56.7 to 60.2)28.3 (26.1 to 30.7)
Pain at the injection site: Moderate14.3 (13.1 to 15.6)3.1 (2.3 to 4.1)
Pain at the injection site: Severe0.2 (0.1 to 0.4)0 (0.0 to 0.2)
Pain at the injection site: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Redness: Any18.8 (17.4 to 20.2)5.2 (4.1 to 6.4)
Redness: Mild10.3 (9.2 to 11.4)3.7 (2.8 to 4.8)
Redness: Moderate8.4 (7.4 to 9.4)1.3 (0.8 to 2.0)
Redness: Severe0.1 (0.0 to 0.3)0.1 (0.0 to 0.5)
Redness: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Swelling: Any14.7 (13.5 to 16.0)2.7 (1.9 to 3.6)
Swelling: Mild8.1 (7.1 to 9.1)2.0 (1.3 to 2.8)
Swelling: Moderate6.6 (5.8 to 7.6)0.7 (0.4 to 1.3)
Swelling: Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
Swelling: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Pain at the injection site: Any71.2 (69.5 to 72.8)28.5 (26.3 to 30.9)
Pain at the injection site: Mild53.6 (51.8 to 55.4)25.6 (23.4 to 27.8)
Pain at the injection site: Moderate17.4 (16.1 to 18.8)2.9 (2.1 to 3.9)
Pain at the injection site: Severe0.2 (0.1 to 0.4)0.1 (0.0 to 0.4)
Pain at the injection site: Grade 40 (0.0 to 0.1)0 (0.0 to 0.4)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\>=0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm),severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Redness: Any15.6 (14.2 to 17.2)—
Redness: Mild9.4 (8.3 to 10.7)—
Redness: Moderate6.1 (5.1 to 7.2)—
Redness: Severe0.1 (0.0 to 0.3)—
Redness: Grade 40 (0.0 to 0.2)—
Swelling: Any12.6 (11.3 to 14.1)—
Swelling: Mild6.5 (5.6 to 7.6)—
Swelling: Moderate6.1 (5.1 to 7.2)—
Swelling: Severe0 (0.0 to 0.2)—
Swelling: Grade 40 (0.0 to 0.2)—
Pain at the injection site: Any69.2 (67.3 to 71.1)—
Pain at the injection site: Mild48.0 (46.0 to 50.1)—
Pain at the injection site: Moderate20.9 (19.3 to 22.7)—
Pain at the injection site: Severe0.3 (0.1 to 0.6)—
Pain at the injection site: Grade 40 (0.0 to 0.2)—
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Fever:>=38.0 deg C2.1 (1.6 to 2.6)1.4 (0.9 to 2.1)
Fever: 38.0 to 38.4 deg C1.2 (0.8 to 1.6)0.7 (0.3 to 1.2)
Fever: >38.4 to 38.9 deg C0.7 (0.4 to 1.1)0.6 (0.3 to 1.1)
Fever: >38.9 to 40.0 deg C0.1 (0.0 to 0.3)0.1 (0.0 to 0.5)
Fever: >40.0 deg C0.0 (0.0 to 0.2)0 (0.0 to 0.2)
Fatigue: Any34.5 (32.8 to 36.2)32.4 (30.1 to 34.8)
Fatigue: Mild22.7 (21.2 to 24.2)21.1 (19.1 to 23.2)
Fatigue: Moderate11.6 (10.5 to 12.8)11.2 (9.6 to 12.9)
Fatigue: Severe0.2 (0.1 to 0.4)0.1 (0.0 to 0.5)
Fatigue: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Headache: Any22.7 (21.2 to 24.2)24.3 (22.2 to 26.5)
Headache: Mild17.1 (15.8 to 18.5)18.0 (16.1 to 20.0)
Headache: Moderate5.5 (4.7 to 6.4)5.9 (4.8 to 7.2)
Headache: Severe0.1 (0.0 to 0.3)0.4 (0.1 to 0.9)
Headache: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Chills: Any5.6 (4.8 to 6.5)5.5 (4.4 to 6.7)
Chills: Mild4.5 (3.8 to 5.2)4.5 (3.5 to 5.7)
Chills: Moderate1.2 (0.8 to 1.6)1.0 (0.5 to 1.6)
Chills: Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
Chills: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Vomiting: Any2.0 (1.6 to 2.6)2.0 (1.3 to 2.8)
Vomiting: Mild1.7 (1.3 to 2.2)1.8 (1.2 to 2.6)
Vomiting: Moderate0.4 (0.2 to 0.6)0.1 (0.0 to 0.5)
Vomiting: Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
Vomiting: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Diarrhea: Any6.4 (5.6 to 7.3)4.9 (3.9 to 6.1)
Diarrhea: Mild5.9 (5.1 to 6.8)4.7 (3.7 to 5.9)
Diarrhea: Moderate0.5 (0.2 to 0.8)0.2 (0.0 to 0.6)
Diarrhea: Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
Diarrhea: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened muscle pain: Any9.3 (8.3 to 10.4)8.2 (6.9 to 9.7)
New or worsened muscle pain: Mild6.7 (5.8 to 7.6)6.3 (5.1 to 7.6)
New or worsened muscle pain: Moderate2.6 (2.1 to 3.3)2.0 (1.3 to 2.8)
New or worsened muscle pain: Severe0.0 (0.0 to 0.2)0 (0.0 to 0.2)
New or worsened muscle pain:G40 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened joint pain:Any3.4 (2.8 to 4.1)4.6 (3.6 to 5.7)
New or worsened joint pain:Mild2.3 (1.8 to 2.9)3.7 (2.8 to 4.7)
New or worsened joint pain:Moderate1.1 (0.8 to 1.6)0.9 (0.5 to 1.5)
New or worsened joint pain:Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened joint pain: G40 (0.0 to 0.1)0 (0.0 to 0.2)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Fever: Any6.3 (5.5 to 7.2)1.4 (0.9 to 2.1)
Fever: >=38.0 to 38.4 deg C3.3 (2.7 to 4.0)0.9 (0.5 to 1.5)
Fever: >38.4 to 38.9 deg C2.3 (1.8 to 2.9)0.3 (0.1 to 0.8)
Fever: >38.9 to 40.0 deg C0.7 (0.4 to 1.0)0.2 (0.0 to 0.6)
Fever: >40.0 deg C0.0 (0.0 to 0.2)0 (0.0 to 0.2)
Fatigue: Any39.2 (37.4 to 40.9)25.2 (23.0 to 27.4)
Fatigue: Mild21.7 (20.3 to 23.2)15.1 (13.4 to 17.0)
Fatigue: Moderate16.6 (15.3 to 17.9)9.8 (8.3 to 11.4)
Fatigue: Severe0.9 (0.6 to 1.3)0.3 (0.1 to 0.7)
Fatigue: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Headache: Any28.4 (26.8 to 30.0)18.7 (16.7 to 20.7)
Headache: Mild18.8 (17.4 to 20.2)13.2 (11.6 to 15.0)
Headache: Moderate9.3 (8.3 to 10.4)5.4 (4.3 to 6.6)
Headache: Severe0.3 (0.1 to 0.5)0.1 (0.0 to 0.4)
Headache: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Chills: Any9.8 (8.8 to 10.9)4.3 (3.4 to 5.5)
Chills: Mild6.7 (5.8 to 7.6)3.4 (2.6 to 4.5)
Chills: Moderate3.1 (2.5 to 3.7)0.9 (0.5 to 1.5)
Chills: Severe0.1 (0.0 to 0.2)0.1 (0.0 to 0.4)
Chills: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Vomiting: Any2.0 (1.6 to 2.6)1.8 (1.2 to 2.6)
Vomiting: Mild1.8 (1.4 to 2.4)1.4 (0.9 to 2.2)
Vomiting: Moderate0.2 (0.1 to 0.4)0.3 (0.1 to 0.8)
Vomiting: Severe0.0 (0.0 to 0.2)0 (0.0 to 0.2)
Vomiting: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
Diarrhea: Any5.4 (4.6 to 6.3)5.0 (4.0 to 6.2)
Diarrhea: Mild4.9 (4.1 to 5.7)4.6 (3.6 to 5.8)
Diarrhea: Moderate0.5 (0.3 to 0.8)0.4 (0.1 to 0.9)
Diarrhea: Severe0.1 (0.0 to 0.2)0 (0.0 to 0.2)
Diarrhea: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened muscle pain:Any12.0 (10.9 to 13.2)6.8 (5.6 to 8.2)
New or worsened muscle pain:Mild8.0 (7.1 to 9.0)4.5 (3.5 to 5.6)
New or worsened muscle pain: Moderate4.0 (3.3 to 4.7)2.4 (1.7 to 3.3)
New or worsened muscle pain: Severe0.0 (0.0 to 0.2)0 (0.0 to 0.2)
New or worsened muscle pain: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened joint pain:Any5.2 (4.4 to 6.0)3.7 (2.9 to 4.8)
New or worsened joint pain:Mild3.4 (2.8 to 4.1)2.8 (2.0 to 3.7)
New or worsened joint pain: Moderate1.8 (1.4 to 2.4)1.0 (0.6 to 1.6)
New or worsened joint pain: Severe0 (0.0 to 0.1)0 (0.0 to 0.2)
New or worsened joint pain: Grade 40 (0.0 to 0.1)0 (0.0 to 0.2)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Fever: >=38.0 deg C6.8 (5.8 to 7.9)—
Fever:38.0 to 38.4 deg C4.1 (3.3 to 5.0)—
Fever: >38.4 to 38.9 deg C1.8 (1.3 to 2.4)—
Fever: >38.9 to 40.0 deg C0.9 (0.5 to 1.4)—
Fever: >40.0 deg C0.0 (0.0 to 0.2)—
Fatigue: Any39.6 (37.6 to 41.7)—
Fatigue: Mild21.0 (19.4 to 22.8)—
Fatigue: Moderate17.3 (15.8 to 18.9)—
Fatigue: Severe1.3 (0.9 to 1.8)—
Fatigue: Grade 40 (0.0 to 0.2)—
Headache: Any26.9 (25.1 to 28.8)—
Headache: Mild16.2 (14.7 to 17.8)—
Headache: Moderate10.3 (9.1 to 11.7)—
Headache: Severe0.4 (0.2 to 0.8)—
Headache: Grade 40 (0.0 to 0.2)—
Chills: Any10.2 (9.0 to 11.5)—
Chills: Mild6.2 (5.2 to 7.3)—
Chills: Moderate3.9 (3.1 to 4.8)—
Chills: Severe0.1 (0.0 to 0.4)—
Chills: Grade 40 (0.0 to 0.2)—
Vomiting: Any2.7 (2.1 to 3.4)—
Vomiting: Mild2.2 (1.6 to 2.9)—
Vomiting: Moderate0.4 (0.2 to 0.8)—
Vomiting: Severe0.0 (0.0 to 0.2)—
Vomiting: Grade 40 (0.0 to 0.2)—
Diarrhea: Any4.6 (3.8 to 5.5)—
Diarrhea: Mild4.3 (3.5 to 5.2)—
Diarrhea: Moderate0.3 (0.1 to 0.6)—
Diarrhea: Severe0.0 (0.0 to 0.2)—
Diarrhea: Grade 40 (0.0 to 0.2)—
New or worsened muscle pain: Any15.5 (14.0 to 17.0)—
New or worsened muscle pain: Mild8.8 (7.7 to 10.0)—
New or worsened muscle pain: Moderate6.5 (5.6 to 7.6)—
New or worsened muscle pain: Severe0.1 (0.0 to 0.4)—
New or worsened muscle pain: Grade 40 (0.0 to 0.2)—
New or worsened joint pain: Any5.7 (4.8 to 6.7)—
New or worsened joint pain: Mild3.5 (2.8 to 4.3)—
New or worsened joint pain: Moderate2.2 (1.6 to 2.9)—
New or worsened joint pain: Severe0.0 (0.0 to 0.2)—
New or worsened joint pain: Grade 40 (0.0 to 0.2)—
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis\[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Redness: Any9.0 (7.9 to 10.3)8.4 (6.9 to 10.2)
Redness: Mild7.7 (6.7 to 8.9)7.5 (6.0 to 9.1)
Redness: Moderate1.2 (0.8 to 1.8)0.9 (0.4 to 1.6)
Redness: Severe0.0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Redness: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Swelling: Any3.9 (3.2 to 4.8)3.1 (2.2 to 4.3)
Swelling: Mild3.4 (2.7 to 4.3)2.5 (1.7 to 3.6)
Swelling: Moderate0.5 (0.2 to 0.8)0.6 (0.2 to 1.2)
Swelling: Severe0 (0.0 to 0.2)0 (0.0 to 0.3)
Swelling: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Pain at the injection site: Any30.3 (28.4 to 32.2)20.6 (18.3 to 23.1)
Pain at the injection site: Mild28.1 (26.3 to 30.0)19.4 (17.2 to 21.8)
Pain at the injection site: Moderate2.2 (1.6 to 2.8)1.1 (0.6 to 1.9)
Pain at the injection site: Severe0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Pain at the injection site: Grade 40 (0.0 to 0.2)0 (0.0 to 0.5)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Redness: Any11.2 (9.9 to 12.7)5.4 (4.1 to 6.9)
Redness: Mild9.6 (8.3 to 10.9)4.6 (3.4 to 6.1)
Redness: Moderate1.6 (1.1 to 2.3)0.8 (0.3 to 1.5)
Redness: Severe0.0 (0.0 to 0.3)0 (0.0 to 0.4)
Redness: Grade 40.0 (0.0 to 0.2)0 (0.0 to 0.4)
Swelling: Any5.6 (4.7 to 6.7)2.0 (1.3 to 3.1)
Swelling: Mild4.4 (3.6 to 5.4)1.8 (1.1 to 2.8)
Swelling: Moderate1.2 (0.8 to 1.8)0.2 (0.0 to 0.7)
Swelling: Severe0 (0.0 to 0.2)0 (0.0 to 0.4)
Swelling: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
Pain at the injection site: Any30.5 (28.5 to 32.5)20.3 (17.9 to 22.9)
Pain at the injection site: Mild28.2 (26.3 to 30.2)19.4 (17.0 to 21.9)
Pain at the injection site: Moderate2.2 (1.6 to 2.9)0.9 (0.4 to 1.6)
Pain at the injection site: Severe0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Pain at the injection site: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Redness: Any10.4 (8.4 to 12.7)4.8 (2.9 to 7.5)
Redness: Mild9.0 (7.1 to 11.2)4.0 (2.2 to 6.5)
Redness: Moderate1.4 (0.7 to 2.4)0.8 (0.2 to 2.3)
Redness: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Redness: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Swelling: Any3.1 (2.0 to 4.6)1.6 (0.6 to 3.4)
Swelling: Mild2.9 (1.8 to 4.3)1.6 (0.6 to 3.4)
Swelling: Moderate0.3 (0.0 to 0.9)0 (0.0 to 1.0)
Swelling: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Swelling: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Pain at the injection site: Any28.0 (24.9 to 31.3)12.8 (9.6 to 16.6)
Pain at the injection site: Mild26.0 (23.0 to 29.2)12.0 (8.9 to 15.7)
Pain at the injection site: Moderate2.0 (1.2 to 3.3)0.8 (0.2 to 2.3)
Pain at the injection site: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Pain at the injection site: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Fever:>=38.0 deg C5.5 (4.6 to 6.5)5.7 (4.4 to 7.2)
Fever: 38.0 to 38.4 deg C3.1 (2.4 to 3.8)2.6 (1.7 to 3.7)
Fever: >38.4 to 38.9 deg C1.5 (1.0 to 2.0)2.1 (1.3 to 3.1)
Fever: >38.9 to 40.0 deg C0.9 (0.6 to 1.4)1.0 (0.5 to 1.8)
Fever: >40.0 deg C0.1 (0.0 to 0.3)0 (0.0 to 0.3)
Fatigue: Any30.6 (28.7 to 32.5)31.9 (29.2 to 34.7)
Fatigue: Mild18.8 (17.2 to 20.4)19.5 (17.3 to 21.9)
Fatigue: Moderate11.5 (10.2 to 12.8)11.6 (9.9 to 13.6)
Fatigue: Severe0.4 (0.2 to 0.7)0.8 (0.4 to 1.5)
Fatigue: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Headache: Any5.1 (4.2 to 6.1)4.8 (3.7 to 6.2)
Headache: Mild3.9 (3.2 to 4.8)3.7 (2.7 to 5.0)
Headache: Moderate1.1 (0.7 to 1.6)1.0 (0.5 to 1.8)
Headache: Severe0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Headache: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Chills: Any2.8 (2.1 to 3.5)2.9 (2.0 to 4.1)
Chills: Mild1.8 (1.3 to 2.4)2.0 (1.3 to 3.0)
Chills: Moderate0.9 (0.5 to 1.3)0.9 (0.4 to 1.6)
Chills: Severe0.1 (0.0 to 0.4)0.1 (0.0 to 0.5)
Chills: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Vomiting: Any3.5 (2.8 to 4.4)2.9 (2.0 to 4.1)
Vomiting: Mild2.9 (2.2 to 3.6)2.1 (1.3 to 3.1)
Vomiting: Moderate0.7 (0.4 to 1.1)0.9 (0.4 to 1.6)
Vomiting: Severe0 (0.0 to 0.2)0 (0.0 to 0.3)
Vomiting: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
Diarrhea: Any8.6 (7.4 to 9.8)8.3 (6.8 to 10.0)
Diarrhea: Mild7.9 (6.8 to 9.0)7.4 (6.0 to 9.1)
Diarrhea: Moderate0.7 (0.4 to 1.1)0.9 (0.4 to 1.6)
Diarrhea: Severe0 (0.0 to 0.2)0 (0.0 to 0.3)
Diarrhea: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
New or worsened muscle pain:Any2.6 (2.0 to 3.3)2.3 (1.5 to 3.4)
New or worsened muscle pain: Mild1.9 (1.4 to 2.6)1.7 (1.1 to 2.7)
New or worsened muscle pain: Moderate0.7 (0.4 to 1.1)0.5 (0.2 to 1.1)
New or worsened muscle pain: Severe0.0 (0.0 to 0.2)0.1 (0.0 to 0.5)
New or worsened muscle pain: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
New or worsened joint pain: Any1.2 (0.8 to 1.7)1.8 (1.1 to 2.8)
New or worsened joint pain:Mild0.9 (0.6 to 1.4)1.4 (0.8 to 2.2)
New or worsened joint pain: Moderate0.2 (0.1 to 0.5)0.4 (0.1 to 1.0)
New or worsened joint pain:Severe0.0 (0.0 to 0.2)0 (0.0 to 0.3)
New or worsened joint pain: Grade 40 (0.0 to 0.2)0 (0.0 to 0.3)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Fever: >=38.0 deg C5.2 (4.3 to 6.2)5.8 (4.4 to 7.4)
Fever:38.0 to 38.4 deg C2.4 (1.8 to 3.2)2.2 (1.4 to 3.3)
Fever: >38.4 to 38.9 deg C1.5 (1.0 to 2.2)2.6 (1.7 to 3.8)
Fever: >38.9 to 40.0 deg C1.1 (0.7 to 1.6)0.9 (0.4 to 1.6)
Fever: >40.0 deg C0.1 (0.0 to 0.4)0.1 (0.0 to 0.5)
Fatigue: Any26.1 (24.2 to 28.0)24.3 (21.7 to 27.0)
Fatigue: Mild15.5 (13.9 to 17.1)14.7 (12.6 to 17.0)
Fatigue: Moderate10.2 (9.0 to 11.6)9.3 (7.6 to 11.2)
Fatigue: Severe0.4 (0.2 to 0.8)0.4 (0.1 to 1.0)
Fatigue: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
Headache: Any4.6 (3.8 to 5.6)4.1 (3.0 to 5.5)
Headache: Mild3.5 (2.7 to 4.3)2.6 (1.7 to 3.8)
Headache: Moderate1.2 (0.7 to 1.7)1.4 (0.8 to 2.4)
Headache: Severe0 (0.0 to 0.2)0.1 (0.0 to 0.5)
Headache: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
Chills: Any3.2 (2.5 to 4.0)2.8 (1.9 to 4.0)
Chills: Mild2.2 (1.6 to 2.9)2.2 (1.4 to 3.3)
Chills: Moderate1.0 (0.6 to 1.5)0.6 (0.2 to 1.3)
Chills: Severe0 (0.0 to 0.2)0 (0.0 to 0.4)
Chills: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
Vomiting: Any3.4 (2.6 to 4.2)3.4 (2.4 to 4.7)
Vomiting: Mild3.0 (2.3 to 3.8)2.9 (2.0 to 4.1)
Vomiting: Moderate0.4 (0.2 to 0.8)0.5 (0.2 to 1.1)
Vomiting: Severe0 (0.0 to 0.2)0 (0.0 to 0.4)
Vomiting: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
Diarrhea: Any6.8 (5.7 to 7.9)8.0 (6.4 to 9.8)
Diarrhea: Mild5.9 (4.9 to 7.0)7.1 (5.6 to 8.9)
Diarrhea: Moderate0.8 (0.5 to 1.3)0.8 (0.3 to 1.5)
Diarrhea: Severe0.1 (0.0 to 0.3)0.1 (0.0 to 0.5)
Diarrhea: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
New or worsened muscle pain: Any2.6 (2.0 to 3.4)2.6 (1.7 to 3.8)
New or worsened muscle pain:Mild1.9 (1.3 to 2.6)2.0 (1.3 to 3.1)
New or worsened muscle pain: Moderate0.8 (0.4 to 1.2)0.6 (0.2 to 1.3)
New or worsened muscle pain: Severe0 (0.0 to 0.2)0 (0.0 to 0.4)
New or worsened muscle pain: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
New or worsened joint pain:Any1.2 (0.8 to 1.8)1.2 (0.6 to 2.0)
New or worsened joint pain:Mild0.9 (0.6 to 1.4)0.9 (0.4 to 1.6)
New or worsened joint pain: Moderate0.3 (0.1 to 0.7)0.3 (0.1 to 0.8)
New or worsened joint pain:Severe0 (0.0 to 0.2)0 (0.0 to 0.4)
New or worsened joint pain: Grade 40 (0.0 to 0.2)0 (0.0 to 0.4)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Fever: >=38.0 deg C5.1 (3.7 to 6.9)5.6 (3.5 to 8.4)
Fever:38.0 to 38.4 deg C2.5 (1.5 to 3.8)2.1 (0.9 to 4.1)
Fever: >38.4 to 38.9 deg C1.8 (1.0 to 2.9)1.9 (0.8 to 3.8)
Fever: >38.9 to 40.0 deg C0.9 (0.4 to 1.8)1.6 (0.6 to 3.4)
Fever: >40.0 deg C0 (0.0 to 0.5)0 (0.0 to 1.0)
Fatigue: Any25.5 (22.5 to 28.7)24.3 (20.0 to 28.9)
Fatigue: Mild16.0 (13.5 to 18.8)14.7 (11.2 to 18.7)
Fatigue: Moderate9.2 (7.3 to 11.4)9.3 (6.6 to 12.7)
Fatigue: Severe0.3 (0.0 to 0.9)0.3 (0.0 to 1.5)
Fatigue: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Headache: Any4.5 (3.2 to 6.2)4.0 (2.3 to 6.5)
Headache: Mild2.9 (1.8 to 4.3)2.9 (1.5 to 5.2)
Headache: Moderate1.6 (0.9 to 2.8)1.1 (0.3 to 2.7)
Headache: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Headache: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Chills: Any2.8 (1.7 to 4.2)2.7 (1.3 to 4.8)
Chills: Mild2.1 (1.3 to 3.4)2.4 (1.1 to 4.5)
Chills: Moderate0.5 (0.1 to 1.3)0.3 (0.0 to 1.5)
Chills: Severe0.1 (0.0 to 0.7)0 (0.0 to 1.0)
Chills: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Vomiting: Any2.0 (1.2 to 3.3)4.3 (2.5 to 6.8)
Vomiting: Mild1.5 (0.8 to 2.6)2.9 (1.5 to 5.2)
Vomiting: Moderate0.5 (0.1 to 1.3)1.3 (0.4 to 3.1)
Vomiting: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Vomiting: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
Diarrhea: Any4.9 (3.5 to 6.7)5.6 (3.5 to 8.4)
Diarrhea: Mild3.8 (2.6 to 5.4)4.5 (2.7 to 7.2)
Diarrhea: Moderate1.1 (0.5 to 2.1)1.1 (0.3 to 2.7)
Diarrhea: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
Diarrhea: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
New or worsened muscle pain: Any1.9 (1.1 to 3.1)1.6 (0.6 to 3.4)
New or worsened muscle pain: Mild1.5 (0.8 to 2.6)1.3 (0.4 to 3.1)
New or worsened muscle pain: Moderate0.4 (0.1 to 1.1)0.3 (0.0 to 1.5)
New or worsened muscle pain: Severe0 (0.0 to 0.5)0 (0.0 to 1.0)
New or worsened muscle pain: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
New or worsened joint pain: Any1.1 (0.5 to 2.1)1.1 (0.3 to 2.7)
New or worsened joint pain: Mild0.9 (0.4 to 1.8)1.1 (0.3 to 2.7)
New or worsened joint pain: Moderate0.1 (0.0 to 0.7)0 (0.0 to 1.0)
New or worsened joint pain: Severe0.1 (0.0 to 0.7)0 (0.0 to 1.0)
New or worsened joint pain: Grade 40 (0.0 to 0.5)0 (0.0 to 1.0)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Redness: Any10.7 (9.2 to 12.4)7.6 (5.7 to 9.8)
Redness: Mild9.8 (8.3 to 11.5)7.2 (5.4 to 9.3)
Redness: Moderate0.9 (0.5 to 1.5)0.4 (0.1 to 1.2)
Redness: Severe0 (0.0 to 0.3)0 (0.0 to 0.5)
Redness: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
Swelling: Any3.8 (2.8 to 4.9)2.5 (1.5 to 4.0)
Swelling: Mild3.3 (2.5 to 4.4)2.2 (1.3 to 3.6)
Swelling: Moderate0.4 (0.2 to 0.9)0.3 (0.0 to 1.0)
Swelling: Severe0 (0.0 to 0.3)0 (0.0 to 0.5)
Swelling: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
Tenderness at injection site: Any17.2 (15.3 to 19.3)12.6 (10.2 to 15.3)
Tenderness at injection site: Mild16.3 (14.4 to 18.3)11.5 (9.2 to 14.1)
Tenderness at injection site:Moderate0.8 (0.4 to 1.5)1.1 (0.5 to 2.2)
Tenderness at injection site:Severe0.1 (0.0 to 0.4)0 (0.0 to 0.5)
Tenderness at injection site: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Redness: Any9.9 (8.3 to 11.6)6.3 (4.6 to 8.4)
Redness: Mild9.1 (7.6 to 10.7)5.9 (4.2 to 7.9)
Redness: Moderate0.8 (0.4 to 1.5)0.5 (0.1 to 1.3)
Redness: Severe0 (0.0 to 0.3)0 (0.0 to 0.6)
Redness: Grade 40 (0.0 to 0.3)0 (0.0 to 0.6)
Swelling: Any4.1 (3.1 to 5.3)1.5 (0.7 to 2.7)
Swelling: Mild3.5 (2.6 to 4.6)1.4 (0.6 to 2.5)
Swelling: Moderate0.6 (0.3 to 1.2)0.2 (0.0 to 0.8)
Swelling: Severe0 (0.0 to 0.3)0 (0.0 to 0.6)
Swelling: Grade 40 (0.0 to 0.3)0 (0.0 to 0.6)
Tenderness at injection site: Any15.4 (13.5 to 17.5)9.3 (7.2 to 11.8)
Tenderness at injection site:Mild13.8 (12.0 to 15.8)7.7 (5.8 to 10.0)
Tenderness at injection site:Moderate1.6 (1.0 to 2.4)1.7 (0.8 to 2.9)
Tenderness at injection site:Severe0.1 (0.0 to 0.4)0 (0.0 to 0.6)
Tenderness at injection site: G40 (0.0 to 0.3)0 (0.0 to 0.6)
PrimaryPhase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Redness: Any7.2 (5.0 to 9.9)5.0 (2.5 to 8.7)
Redness: Mild5.0 (3.2 to 7.4)4.5 (2.2 to 8.1)
Redness: Moderate2.0 (0.9 to 3.7)0.5 (0.0 to 2.5)
Redness: Severe0.2 (0.0 to 1.2)0 (0.0 to 1.6)
Redness: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
Swelling: Any3.3 (1.8 to 5.3)2.3 (0.7 to 5.2)
Swelling: Mild2.0 (0.9 to 3.7)2.3 (0.7 to 5.2)
Swelling: Moderate1.3 (0.5 to 2.8)0 (0.0 to 1.6)
Swelling: Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Swelling: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
Tenderness at injection site:Any14.7 (11.6 to 18.3)9.9 (6.3 to 14.6)
Tenderness at injection site:Mild13.0 (10.0 to 16.4)8.6 (5.2 to 13.0)
Tenderness at injection site: Moderate1.8 (0.8 to 3.4)1.4 (0.3 to 3.9)
Tenderness at injection site:Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Tenderness at injection site: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 1
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Fever: >=38.0 deg C7.2 (5.9 to 8.7)7.4 (5.6 to 9.6)
Fever: 38.0 to 38.4 deg C3.4 (2.5 to 4.5)3.5 (2.3 to 5.1)
Fever: >38.4 to 38.9 deg C2.2 (1.5 to 3.1)2.5 (1.5 to 4.0)
Fever: >38.9 to 40.0 deg C1.5 (1.0 to 2.3)1.3 (0.6 to 2.4)
Fever: >40.0 deg C0.1 (0.0 to 0.4)0.1 (0.0 to 0.8)
Decreased appetite: Any22.7 (20.5 to 24.9)21.2 (18.3 to 24.5)
Decreased appetite: Mild12.4 (10.7 to 14.2)12.0 (9.7 to 14.7)
Decreased appetite: Moderate10.1 (8.6 to 11.8)8.9 (6.9 to 11.3)
Decreased appetite: Severe0.2 (0.0 to 0.6)0.3 (0.0 to 1.0)
Decreased appetite: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
Drowsiness: Any27.8 (25.5 to 30.2)30.0 (26.7 to 33.6)
Drowsiness: Mild22.0 (19.8 to 24.2)22.7 (19.6 to 25.9)
Drowsiness: Moderate5.6 (4.5 to 6.9)6.9 (5.2 to 9.1)
Drowsiness: Severe0.2 (0.0 to 0.6)0.4 (0.1 to 1.2)
Drowsiness: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
Irritability: Any51.0 (48.4 to 53.6)48.2 (44.4 to 51.9)
Irritability: Mild20.6 (18.6 to 22.8)18.3 (15.5 to 21.3)
Irritability: Moderate29.7 (27.3 to 32.1)29.6 (26.3 to 33.1)
Irritability: Severe0.7 (0.3 to 1.3)0.3 (0.0 to 1.0)
Irritability: Grade 40 (0.0 to 0.3)0 (0.0 to 0.5)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Fever: >=38.0 deg C7.6 (6.3 to 9.2)6.5 (4.7 to 8.6)
Fever: 38.0 to 38.4 deg C3.6 (2.7 to 4.8)3.6 (2.3 to 5.3)
Fever: >38.4 to 38.9 deg C2.0 (1.4 to 3.0)1.7 (0.8 to 2.9)
Fever: >38.9 to 40.0 deg C1.9 (1.2 to 2.8)1.2 (0.5 to 2.4)
Fever: >40.0 deg C0.1 (0.0 to 0.4)0 (0.0 to 0.6)
Decreased appetite: Any22.5 (20.3 to 24.9)19.4 (16.5 to 22.6)
Decreased appetite: Mild13.9 (12.1 to 15.9)11.3 (9.0 to 14.0)
Decreased appetite: Moderate8.1 (6.7 to 9.8)8.0 (6.0 to 10.3)
Decreased appetite: Severe0.5 (0.2 to 1.0)0.2 (0.0 to 0.8)
Decreased appetite: Grade 40 (0.0 to 0.3)0 (0.0 to 0.6)
Drowsiness: Any24.1 (21.8 to 26.5)21.4 (18.3 to 24.7)
Drowsiness: Mild17.8 (15.8 to 20.0)16.9 (14.1 to 19.9)
Drowsiness: Moderate6.0 (4.8 to 7.4)4.4 (2.9 to 6.2)
Drowsiness: Severe0.3 (0.1 to 0.8)0.2 (0.0 to 0.8)
Drowsiness: Grade 40 (0.0 to 0.3)0 (0.0 to 0.6)
Irritability: Any46.9 (44.2 to 49.6)41.4 (37.6 to 45.3)
Irritability: Mild18.5 (16.4 to 20.7)15.8 (13.1 to 18.8)
Irritability: Moderate27.8 (25.4 to 30.3)24.7 (21.5 to 28.2)
Irritability: Severe0.6 (0.3 to 1.2)0.9 (0.3 to 2.0)
Irritability: Grade 40 (0.0 to 0.3)0 (0.0 to 0.6)
PrimaryPhase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age

Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Phase 2/3: From Day 1 to Day 7 after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Fever:>=38.0 deg C6.1 (4.1 to 8.7)5.9 (3.2 to 9.8)
Fever:38.0 to 38.4 deg C3.3 (1.8 to 5.3)3.2 (1.3 to 6.4)
Fever: >38.4 to 38.9 deg C1.3 (0.5 to 2.8)1.8 (0.5 to 4.5)
Fever: >38.9 to 40.0 deg C1.1 (0.4 to 2.5)0.9 (0.1 to 3.2)
Fever: >40.0 deg C0.4 (0.1 to 1.6)0 (0.0 to 1.6)
Decreased appetite: Any19.6 (16.0 to 23.5)13.1 (8.9 to 18.2)
Decreased appetite: Mild11.2 (8.5 to 14.5)7.2 (4.2 to 11.4)
Decreased appetite: Moderate7.5 (5.2 to 10.3)5.9 (3.2 to 9.8)
Decreased appetite: Severe0.9 (0.2 to 2.2)0 (0.0 to 1.6)
Decreased appetite: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
Drowsiness: Any21.5 (17.8 to 25.6)12.2 (8.2 to 17.2)
Drowsiness: Mild15.8 (12.6 to 19.5)9.0 (5.6 to 13.6)
Drowsiness: Moderate5.3 (3.4 to 7.7)2.7 (1.0 to 5.8)
Drowsiness: Severe0.4 (0.1 to 1.6)0.5 (0.0 to 2.5)
Drowsiness: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
Irritability: Any42.0 (37.4 to 46.7)36.9 (30.6 to 43.7)
Irritability: Mild15.8 (12.6 to 19.5)15.3 (10.8 to 20.7)
Irritability: Moderate25.7 (21.8 to 30.0)21.6 (16.4 to 27.6)
Irritability: Severe0.4 (0.1 to 1.6)0 (0.0 to 1.6)
Irritability: Grade 40 (0.0 to 0.8)0 (0.0 to 1.6)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age10.7 (9.6 to 11.9)9.8 (8.3 to 11.3)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age8.0 (7.0 to 9.2)—
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age0.3 (0.1 to 0.5)0.1 (0.0 to 0.5)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age
Percentage of participantsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age0.4 (0.2 to 0.8)—
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age13.1 (11.8 to 14.6)13.0 (11.1 to 15.0)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age4.5 (3.2 to 6.1)6.4 (4.2 to 9.3)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age0.5 (0.2 to 0.8)0.9 (0.4 to 1.6)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age0.3 (0.1 to 1.0)0 (0.0 to 0.9)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age21.5 (19.4 to 23.7)19.9 (17.1 to 23.0)
PrimaryPhase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age10.4 (7.8 to 13.4)7.6 (4.6 to 11.7)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 1 to 6 Months after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age1.7 (1.1 to 2.5)2.4 (1.4 to 3.8)
PrimaryPhase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Phase 2/3: From Dose 3 to 6 Months after Dose 3
Reported as:
Number · Percentage of participants
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age0.2 (0.0 to 1.1)0 (0.0 to 1.5)
PrimaryPhase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection

GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.

Time frame:
C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Geometric mean · Titer
Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection
TiterPhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection1197.6 (1106.1 to 1296.6)1146.5 (1045.5 to 1257.2)
Statistical analysis
  • Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age · Geometric mean ratio: 1.04 · 95% CI 0.93 to 1.18
PrimaryPhase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

Seroresponse is defined as achieving a \>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
Percentage of participantsPhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgeHistorical Cohort:C4591001 BNT162b2(30 mcg)16 to 25 Years
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection99.2 (97.3 to 99.9)99.2 (97.2 to 99.9)
Statistical analysis
  • Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age · Difference in percentage: 0.0 · 95% CI -2.0 to 2.2
PrimaryPhase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.

Time frame:
C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Geometric mean · Titer
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
TiterPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection763.9 (688.5 to 847.5)1255.4 (1131.2 to 1393.3)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age · Geometric mean ratio: 0.61 · 95% CI 0.53 to 0.70
PrimaryPhase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

Seroresponse is defined as achieving a \>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Number · Percentage of Participants
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
Percentage of ParticipantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection96.7 (93.6 to 98.6)97.6 (94.9 to 99.1)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age · Difference in percentage: -0.9 · 95% CI -4.3 to 2.3
PrimaryPhase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection

GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.

Time frame:
C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Geometric mean · Titers
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
TitersPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection979.7 (893.2 to 1074.6)946.8 (850.8 to 1053.7)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age · Geometric mean ratio: 1.03 · 95% CI 0.90 to 1.19
PrimaryPhase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection

Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Number · Percentage of Participants
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection
Percentage of ParticipantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection98.0 (95.3 to 99.3)96.2 (92.9 to 98.3)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age · Difference in percentage: 1.7 · 95% CI -1.4 to 5.2
PrimaryPhase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection

GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.

Time frame:
C4591007 (>=2 to <5 years):1 Month after Dose 2 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2
Reported as:
Geometric mean · Titers
Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection
TitersPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection1535.2 (1388.2 to 1697.8)1180.0 (1066.6 to 1305.4)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age · Geometric mean ratio: 1.30 · 95% CI 1.13 to 1.50
PrimaryPhase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection

Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
C4591007 (>=2 to <5 years): 1 Month after Dose 3 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection100.0 (97.4 to 100.0)98.8 (95.8 to 99.9)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age · Difference in percentages: 1.2 · 95% CI -1.5 to 4.2
PrimaryPhase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection

GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.

Time frame:
C4591007 (>=6 months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2
Reported as:
Geometric mean · Titers
Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection
TitersPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection1406.5 (1211.3 to 1633.1)1180.0 (1066.6 to 1305.4)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age · Geometric mean ratio: 1.19 · 95% CI 1.00 to 1.42
PrimaryPhase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection

Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
C4591007 (>=6 Months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 month after Dose 2
Reported as:
Number · Percentage of participants
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection
Percentage of participantsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgeHistorical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection100.0 (95.5 to 100.0)98.8 (95.8 to 99.9)
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age · Difference in percentage: 1.2 · 95% CI -3.4 to 4.2
SecondaryPhase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection

GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

Time frame:
Phase 1: 7 days post Dose 2
Reported as:
Geometric mean · Titer
Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection
TiterPhase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age
Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection1643.8 (1151.3 to 2347.1)
SecondaryPhase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection

GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

Time frame:
Phase 1: 7 days post Dose 2
Reported as:
Geometric mean · Titer
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection
TiterPhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection1350.4 (973.1 to 1873.9)2059.5 (1679.1 to 2526.0)
SecondaryPhase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection

GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.

Time frame:
Phase 1: 7 days post Dose 2
Reported as:
Geometric mean · Titer
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection
TiterPhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of AgePhase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection4162.6 (2584.7 to 6704.0)4583.4 (2802.9 to 7494.8)242.1 (199.6 to 293.7)—
SecondaryPhase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
Phase 2/3: Before Dose 1 and 1 Month after Dose 2
Reported as:
Geometric mean · Titer
Phase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection
TiterPhase 2/3:BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Pre-dose 110.1 (9.9 to 10.3)10.0 (10.0 to 10.0)
1 Month after Dose 21197.6 (1106.1 to 1296.6)10.7 (9.7 to 11.8)
SecondaryPhase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.

Time frame:
Phase 2/3: From Dose 3 set: Pre-Dose 3 and 1 Month after Dose 3
Reported as:
Geometric mean · Titer
Phase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection
TiterPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Pre-Dose 3271.0 (229.1 to 320.6)—
1 Month after Dose 32720.9 (2280.1 to 3247.0)—
SecondaryPhase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.

Time frame:
Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
Reported as:
Geometric mean · Titer
Phase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
TiterPhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Pre-Dose 120.7 (20.3 to 21.2)20.5 (20.5 to 20.5)
Pre-Dose 3401.1 (361.7 to 444.7)20.9 (20.1 to 21.8)
1 Month after Dose 31535.2 (1388.2 to 1697.8)22.9 (19.5 to 26.8)
SecondaryPhase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.

Time frame:
Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
Reported as:
Geometric mean · Titer
Phase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
TiterPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Pre- Dose 120.8 (20.2 to 21.5)20.5 (20.5 to 20.5)
Pre-Dose 3317.0 (268.8 to 373.9)24.2 (19.7 to 29.8)
1 Month After Dose 31406.5 (1211.3 to 1633.1)22.3 (18.8 to 26.4)
SecondaryPhase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection

GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\* LLOQ in the analysis.

Time frame:
Phase 2/3: From Dose 1 to 1 Month after Dose 2
Reported as:
Geometric mean · Fold rise
Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection
Fold risePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection118.2 (109.2 to 127.9)1.1 (1.0 to 1.2)
SecondaryPhase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection

GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.

Time frame:
Phase 2/3: From Dose 3 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection
Fold risePhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection10.0 (8.1 to 12.4)—
SecondaryPhase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

Time frame:
Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3
Reported as:
Geometric mean · Fold rise
Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection
Fold risePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of Age
Pre-Dose 319.2 (17.4 to 21.3)1.0 (1.0 to 1.1)
1 Month after Dose 373.3 (66.3 to 81.1)1.1 (0.9 to 1.3)
SecondaryPhase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.

Time frame:
Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3
Reported as:
Geometric mean · Fold rise
Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection
Fold risePhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of Age
Pre-Dose 315.4 (12.9 to 18.3)1.2 (1.0 to 1.5)
1 Month after Dose 368.4 (58.2 to 80.4)1.1 (0.9 to 1.3)
SecondaryPhase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age

COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.

Time frame:
Phase 2/3: From 7 days after Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)
Reported as:
Number · Events per 1000 person-years
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age
Events per 1000 person-yearsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age16.920143.836
Statistical analysis
  • Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age vs Phase 2/3: Placebo: 5 to <12 Years of Age · Vaccine efficacy: 88.2 · 95% CI 76.2 to 94.7
SecondaryPhase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age

COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.

Time frame:
Phase 2/3: From 7 Days After Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)
Reported as:
Number · Events per 1000 person-years
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age
Events per 1000 person-yearsPhase 2/3:BNT162b2 (10 mcg):5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of Age
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age18.377128.834
Statistical analysis
  • Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age vs Phase 2/3: Placebo: 5 to <12 Years of Age · Vaccine efficacy: 85.7 · 95% CI 72.4 to 93.2
SecondaryPhase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age

COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.

Time frame:
Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)
Reported as:
Number · Events per 1000 person-years
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age
Events per 1000 person-yearsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of AgePhase 2/3: Placebo: 6 Months to <5 Years of Age
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age104.839388.889
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age vs Phase 2/3: Placebo: 6 Months to <5 Years of Age · Vaccine efficacy: 73.2 · 95% CI 43.8 to 87.6
SecondaryPhase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age

COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.

Time frame:
Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)
Reported as:
Number · Events per 1000 person-years
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age
Events per 1000 person-yearsPhase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of AgePhase 2/3: Placebo: 6 Months to <5 Years of Age
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age93.960343.284
Statistical analysis
  • Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age vs Phase 2/3: Placebo: 6 Months to <5 Years of Age · Vaccine efficacy: 72.5 · 95% CI 44.3 to 86.9

Adverse events

Collected over Other AEs (non-SAEs): from Dose(D) 1 to 1 month after D2 and D3 to 1 month after D3. Local reactions/systemic events: Day 1 to 7 after each dose. SAEs: From D1 to 6 months after D2 and from D3 to 6 months after D3 (maximum up to 28.5 months for Phase 1, 30.5 months for Phase 2/3 during blinded follow-up period and 24.2 months for Phase 2/3 during OL period). 'OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)': SAEs: From D2 to 6 months after D2 and non-SAEs: from D1 to 1 month after D2. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2)0/16 (0%)0/16 (0%)10/16 (62.5%)
Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3)0/15 (0%)0/15 (0%)7/15 (46.7%)
Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)0/16 (0%)0/16 (0%)10/16 (62.5%)
Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)0/32 (0%)0/32 (0%)32/32 (100%)
Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3)0/13 (0%)0/13 (0%)0/13 (0%)
Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3)0/27 (0%)0/27 (0%)17/27 (63%)
Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)0/16 (0%)0/16 (0%)16/16 (100%)
Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2)0/16 (0%)0/16 (0%)16/16 (100%)
Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2)0/4 (0%)0/4 (0%)4/4 (100%)
Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2)0/12 (0%)0/12 (0%)11/12 (91.7%)
Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)0/38 (0%)0/38 (0%)35/38 (92.1%)
Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)0/2 (0%)0/2 (0%)1/2 (50%)
Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)0/1,458 (0%)24/1,458 (1.6%)1,154/1,458 (79.1%)
BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2)0/718 (0%)17/718 (2.4%)550/718 (76.6%)
BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)0/1,324 (0%)1/1,324 (0.1%)267/1,324 (20.2%)
BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3)0/237 (0%)0/237 (0%)119/237 (50.2%)
BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)0/2,368 (0%)11/2,368 (0.5%)1,661/2,368 (70.1%)
BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2)0/1,173 (0%)10/1,173 (0.9%)778/1,173 (66.3%)
BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)0/1,889 (0%)3/1,889 (0.2%)398/1,889 (21.1%)
BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3)0/405 (0%)0/405 (0%)152/405 (37.5%)
BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)0/3,109 (0%)8/3,109 (0.3%)2,821/3,109 (90.7%)
BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2)0/1,538 (0%)3/1,538 (0.2%)1,083/1,538 (70.4%)
BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)0/2,410 (0%)10/2,410 (0.4%)1,794/2,410 (74.4%)
BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2)0/518 (0%)1/518 (0.2%)442/518 (85.3%)
BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2)0/260 (0%)0/260 (0%)163/260 (62.7%)
BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3)0/418 (0%)2/418 (0.5%)319/418 (76.3%)
BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2)0/487 (0%)2/487 (0.4%)414/487 (85%)
BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3)0/433 (0%)0/433 (0%)285/433 (65.8%)
OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)0/581 (0%)5/581 (0.9%)52/581 (9%)
OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)0/534 (0%)11/534 (2.1%)6/534 (1.1%)
OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)0/706 (0%)2/706 (0.3%)31/706 (4.4%)
OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)0/581 (0%)6/581 (1%)8/581 (1.4%)
OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)0/1,262 (0%)4/1,262 (0.3%)159/1,262 (12.6%)
OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)0/243 (0%)2/243 (0.8%)52/243 (21.4%)
OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)0/957 (0%)3/957 (0.3%)75/957 (7.8%)
OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)0/91 (0%)2/91 (2.2%)0/91 (0%)
OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)0/202 (0%)0/202 (0%)20/202 (9.9%)
OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)0/9 (0%)0/9 (0%)0/9 (0%)
OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3)0/113 (0%)0/113 (0%)3/113 (2.7%)
OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3)0/145 (0%)2/145 (1.4%)17/145 (11.7%)
BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3)0/204 (0%)1/204 (0.5%)13/204 (6.4%)
OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)0/81 (0%)0/81 (0%)10/81 (12.3%)
OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)0/13 (0%)0/13 (0%)0/13 (0%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventPhase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3)Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3)Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3)Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2)Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2)Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2)Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3)BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3)BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2)BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2)BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3)BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2)BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3)OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3)BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)
PharyngitisInfections and infestations0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9571/910/2020/90/1130/1450/2040/810/13
Conversion disorderPsychiatric disorders0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9571/910/2020/90/1130/1450/2040/810/13
Addison's diseaseEndocrine disorders0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1131/1450/2040/810/13
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1131/1450/2040/810/13
SeizureNervous system disorders0/160/150/160/320/130/270/160/160/40/120/380/21/14580/7180/13240/2370/23680/11730/18890/4050/31090/15381/24100/5180/2600/4180/4870/4330/5811/5340/7060/5810/12621/2430/9570/910/2020/90/1130/1451/2040/810/13
BronchiolitisInfections and infestations0/160/150/160/320/130/270/160/160/40/120/380/23/14583/7180/13240/2370/23681/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
PyelonephritisInfections and infestations0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7061/5810/12621/2430/9570/910/2020/90/1130/1450/2040/810/13
Respiratory syncytial virus bronchiolitisInfections and infestations0/160/150/160/320/130/270/160/160/40/120/380/25/14581/7181/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5812/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
CyanosisVascular disorders0/160/150/160/320/130/270/160/160/40/120/380/20/14582/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Sickle cell anaemia with crisisBlood and lymphatic system disorders0/160/150/160/320/130/270/160/160/40/120/380/20/14580/7180/13240/2370/23680/11730/18890/4050/31090/15380/24100/5180/2601/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Most frequent other events
Showing 10 of 77
Most frequent other events
EventPhase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3)Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3)Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3)Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2)Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2)Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2)Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3)BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3)BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2)BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2)BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2)BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3)BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2)BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3)OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3)BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders0/160/150/164/320/130/272/165/164/41/123/380/20/14580/7180/13240/237106/236850/117315/18896/405561/3109192/1538350/241081/51831/26073/418167/48776/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Fatigue (FATIGUE)General disorders0/160/155/1623/320/138/2714/1613/164/410/1215/381/20/14580/7180/13240/237977/2368487/1173202/188991/4051614/3109641/1538897/2410221/518105/260153/418255/487149/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Injection site erythema (REDNESS)General disorders3/162/150/169/320/131/278/163/164/43/1211/380/2237/145883/71833/132411/237379/2368136/117383/188918/405806/3109148/1538354/241092/51817/26067/41812/48714/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Injection site pain (PAIN)General disorders0/160/157/1621/320/139/2714/1615/164/411/1233/381/20/14580/7180/13240/237998/2368357/1173222/188948/4052603/3109661/15381568/2410397/51879/260273/418384/487257/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Pyrexia (FEVER)General disorders2/161/151/169/320/130/273/164/164/44/121/380/2184/145887/71828/132413/237224/2368121/117341/188921/405243/310940/1538154/241016/5188/26018/41833/48714/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Headache (HEADACHE)Nervous system disorders0/160/152/168/320/131/2710/1611/163/46/1213/381/20/14580/7180/13240/237191/236886/117336/188915/4051193/3109506/1538610/2410163/51877/26093/418228/487143/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Chills (CHILLS)General disorders0/160/151/163/320/130/275/167/163/45/126/381/20/14580/7180/13240/237125/236859/117322/188910/405413/3109129/1538231/241050/51831/26035/41888/48752/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Injection site swelling (SWELLING)General disorders1/161/150/164/320/130/278/163/163/41/125/380/294/145826/71815/13245/237182/236853/117325/18896/405622/310978/1538286/241069/51814/26050/41827/48712/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Irritability (IRRITABILITY)Psychiatric disorders8/164/150/160/320/130/270/160/160/40/120/380/2932/1458431/718191/132482/2370/23680/11730/18890/4050/31090/15380/24100/5180/2600/4180/4870/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13
Diarrhea (DIARRHEA)Gastrointestinal disorders0/160/151/165/320/131/271/161/162/40/120/380/20/14580/7180/13240/237305/2368160/117339/188921/405320/3109138/1538104/241040/51826/26019/41866/48718/4330/5810/5340/7060/5810/12620/2430/9570/910/2020/90/1130/1450/2040/810/13

Baseline characteristics

Safety set included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.

Age, Customized
Age, Customized(Participants)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: 5 to <12 Years 30/30 mcgPhase 1: 5 to <12 Years 30/10 mcgPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of AgeTotal
Infants and toddlers (28 days-23 months)16000000145871800000002192
Children (2-11 years)01632161641200236811733109153851826009062
Adolescents (12-17 years)000000000000000487487
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: 5 to <12 Years 30/30 mcgPhase 1: 5 to <12 Years 30/10 mcgPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of AgeTotal
Female671311616728372119757015007592521202165764
Male1091951036730346117160316097792661402715977
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: 5 to <12 Years 30/30 mcgPhase 1: 5 to <12 Years 30/10 mcgPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of AgeTotal
Hispanic or Latino30120202489342619352626552344222267
Not Hispanic or Latino13163114162121205620193497925791273466226659451
Unknown or Not Reported000000055814000023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of AgePhase 1: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 2 to <5 Years of AgePhase 1: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 1: BNT162b2 (20 mcg): 5 to <12 Years of AgePhase 1: 5 to <12 Years 30/30 mcgPhase 1: 5 to <12 Years 30/10 mcgPhase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of AgePhase 2/3: Placebo: 6 Months to <2 Years of AgePhase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of AgePhase 2/3: Placebo: 2 to <5 Years of AgePhase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of AgePhase 2/3: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of AgePhase 2/3: Troponin Group: Placebo: 5 to <12 Years of AgePhase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of AgeTotal
American Indian or Alaska Native0010000414413411209242
Asian1122201101511479225611849164843
Native Hawaiian or Other Pacific Islander0000000002110000013
Black or African American0023000733413871179101191140671
White131225111341011265621870913240411994252192289034
More than one race2320101149651898623510623131876
Unknown or Not Reported000000055186121010562
08

Study locations

128 sites
  • University of Alabama at Birmingham - School of Medicine
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • SCPMG/Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Matrix Clinical Research
    Los Angeles, California 90057, United States
  • Madera Family Medical Group
    Madera, California 93637, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Clinical & Translational Research Unit (CTRU) & Spectrum BioBank, Stanford University
    Palo Alto, California 94304, United States
  • Lucile Packard Children's Hospital Stanford
    Palo Alto, California 94304, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Center for Clinical Trials
    Paramount, California 90723, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Kaiser Permanente Sacramento
    Sacramento, California 95815, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Stanford Health Care Investigational Drug Service
    Stanford, California 94305, United States
  • Stanford Health Care
    Stanford, California 94305, United States
  • Bayview Research Group, LLC
    Valley Village, California 91607, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Emerson Clinical Research Institute
    Washington D.C., District of Columbia 20009, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Velocity Clinical Research, Washington DC
    Washington D.C., District of Columbia 20016, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Emory Children's Center Illness POD
    Atlanta, Georgia 30322, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Meridian Clinical Research, LLC
    Macon, Georgia 31210, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Novak Center for Children's Health
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Louisiana State University Health Sciences Shreveport
    Shreveport, Louisiana 71101, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Michigan Center of Medical Research
    Bingham Farms, Michigan 48025, United States
  • SKY Integrative Medical Center/SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Meridian Clinical Research, LLC
    Hastings, Nebraska 68901, United States
  • Velocity Clinical Research, Lincoln
    Lincoln, Nebraska 68510, United States
  • Children's Hospital & Medical Center
    Omaha, Nebraska 68114, United States
  • Children's Physician's Clinic, Spring Valley
    Omaha, Nebraska 68117, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Rutgers University
    New Brunswick, New Jersey 08901, United States
  • Meridian Clinical Research LLC
    Binghamton, New York 13905, United States
  • Advanced Specialty Care
    Commack, New York 11725, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Atrium Health-STRIVE Vaccine Research Clinic
    Charlotte, North Carolina 28207, United States
  • Teen Health Connection (study visits)
    Charlotte, North Carolina 28211, United States
  • Duke University - Main Hospital and Clinics
    Durham, North Carolina 27703, United States
  • Atrium Health-STRIVE Vaccine Research Clinic (study visits)
    Matthews, North Carolina 28105, United States
  • Cincinnati Children's Hospital Medical Center Vaccine Research Center
    Cincinnati, Ohio 45229, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • PriMed Clinical Research
    Dayton, Ohio 45429, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • AHN Erie Health + Wellness Pavillion: West
    Erie, Pennsylvania 16506, United States
  • Velocity Clinical Research-Providence
    East Greenwich, Rhode Island 02818, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Coastal Pediatric Research
    Summerville, South Carolina 29486, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Innovo Research - Austin Regional Clinic
    Austin, Texas 78726, United States
  • Driscoll Children's Hospital
    Corpus Christi, Texas 78411, United States
  • Cedar Health Research
    Dallas, Texas 75251, United States
  • Bay Colony Pediatrics
    Dickinson, Texas 77539, United States
  • Proactive Clinical Research, LLC
    Edinburg, Texas 78539, United States
  • Village Health Partners (Patient Seen Address)
    Frisco, Texas 75033, United States
  • Helios Clinical Research - HOU
    Houston, Texas 77008, United States
  • Helios Clinical Research
    Houston, Texas 77008, United States
  • HG Pediatrics
    Houston, Texas 77008, United States
  • Van Tran Family Practice
    Houston, Texas 77008, United States
  • Texas Children's Hospital - Clinical Research Center
    Houston, Texas 77030, United States
  • West Houston Clinical Research Services
    Houston, Texas 77055, United States
  • DM Clinical Research - MDC
    Houston, Texas 77065, United States
  • Pediatric Associates
    Houston, Texas 77087, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)
    Charlottesville, Virginia 22902, United States
  • Virginia Research Center
    Midlothian, Virginia 23114, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital Santo Antônio - Obras Sociais Irmã Dulce/ Centro de Pesquisa Clínica - CPEC
    Salvador, Estado de Bahia 40415-006, Brazil
  • Santa Casa De Misericórdia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Serviço de Infectologia e Controle de Infecção Hospitalar de Curitiba/ Centro Médico São Francisco
    Curitiba, Paraná 80810-050, Brazil
  • CePCLIN - Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda
    Natal, Rio Grande do Norte 59025-050, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda.
    São Paulo, 04266-010, Brazil
  • FVR, Oulu Clinic
    Oulu, North Ostrobothnia 90220, Finland
  • FVR, Järvenpää Clinic
    Jarvenpaa, Uusimaa 04400, Finland
  • FVR, Espoo Clinic
    Espoo, 02230, Finland
  • FVR, Helsinki South Clinic
    Helsinki, 00100, Finland
  • MeVac - Meilahti Vaccine Research Center
    Helsinki, 00290, Finland

Showing the first 100 of 128 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. PubMed 39197299 ↗
  • Simoes EAF, Klein NP, Sabharwal C, Gurtman A, Kitchin N, Ukkonen B, Korbal P, Zou J, Xie X, Sarwar UN, Xu X, Lockhart S, Cunliffe L, Lu C, Ma H, Swanson KA, Koury K, Shi PY, Cooper D, Tureci Ӧ, Jansen KU, Sahin U, Gruber WC. Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):234-238. doi: 10.1093/jpids/piad015. PubMed 36929216 ↗
  • Munoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martinez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Tureci O, Sahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N Engl J Med. 2023 Feb 16;388(7):621-634. doi: 10.1056/NEJMoa2211031. PubMed 36791162 ↗
  • Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Munoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simoes EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Ramet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Tureci O, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9. PubMed 34752019 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Oct 2023, 30 months.

Results were first posted in May 2026, 2 years 7 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 30 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 25, 2021
StartActual
Mar 24, 2021
Primary completionActual
Oct 4, 2023
CompletionActual
Dec 8, 2023
Results first posted
May 28, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04816643
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Mar 24, 2021
Primary completion
Oct 4, 2023
Completion
Dec 8, 2023
Results posted
May 28, 2026
Last update
May 28, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Biological Products · BNT162 Vaccine

Start the discussion